

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 29 May 2001 (29.05.01)	Applicant's or agent's file reference 00/20788
International application No. PCT/IL00/00510	Priority date (day/month/year) 01 September 1999 (01.09.99)
International filing date (day/month/year) 27 August 2000 (27.08.00)	
Applicant EREZ, Mordechai et al	

1. The designated Office is hereby notified of its election made:

☒

in the demand filed with the International Preliminary Examining Authority on:

20 March 2001 (20.03.01)

☐

in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Claudio Borton
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15656 A2

- (51) International Patent Classification⁷: **A61K** (74) Agent: EHRlich, Gal; G.E. Ehrlich (1995) Ltd., Bezalel Street 28, 52521 Ramat Gan (IL).
- (21) International Application Number: **PCT/IL00/00510**
- (22) International Filing Date: 27 August 2000 (27.08.2000)
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
131685 1 September 1999 (01.09.1999) **IL**
- (71) Applicant (for all designated States except US): **TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.** [IL/IL]; Senate House, Technion City, 32000 Haifa (IL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **EREZ, Mordechai** [IL/IL]; 19 Shmuel Barkai Street, 69697 Tel Aviv (IL). **LEVY, Ofra** [IL/IL]; 8 Gedera Street, 49724 Petah Tikva (IL). **KEINAN, Ehud** [IL/IL]; 8 Moran Street, 23840 Timrat (IL).

(54) Title: **TRICYCLIC COMPOUNDS AND THEIR USES AS ANTIARRHYTHMIC ANTIFIBRILLATORY AND DEFIBRILLATORY AGENTS**



(57) Abstract: A compound having a general formula (II) wherein R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof, and the new therapeutic uses thereof and similar compounds as defibrillating, and/or anti-fibrillatory, and/or anti-arrhythmic and/or anti-ischemic drugs.

WO 01/15656 A2

PATENT COOPERATION TREATY
PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 00/20788	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/IL00/00510	International filing date (<i>day/month/year</i>) 27 August 2000 (27.08.2000)	(Earliest) Priority Date (<i>day/month/year</i>) 01 September 1999 (01.09.1999)
Applicant TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 2 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the Report

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐

contained in the international application in written form.

☐

filed together with the international application in computer readable form.

☐

furnished subsequently to this Authority in written form.

☐

furnished subsequently to this Authority in computer readable form.

☐

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (See Box II).

4. With regard to the title,

☒

the text is approved as submitted by the applicant.

☐

the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒

the text is approved as submitted by the applicant.

☐

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐

as suggested by the applicant.

☐

because the applicant failed to suggest a figure.

☐

because this figure better characterizes the invention.



None of the figures

TRICYCLIC COMPOUNDS AND THEIR USES AS ANTIARRHYTHMIC
ANTIFIBRILLATORY AND DEFIBRILLATORY AGENTS

FIELD AND BACKGROUND OF THE INVENTION

5 The present invention relates to tricyclic compounds of the
11-oxo-dibenzodiazepin and dibenzoazepin families, and their new therapeutic
uses as defibrillating, and/or anti-fibrillatory, and/or anti-arrhythmic and/or
anti-ischemic drugs. More particularly, the present invention relates to
5(N-acyl)-derivatives and 5(N- β -aminoalcohol)-derivatives of
10 11-Oxo-10,11-dihydro-dibenzo[b,e] [1,4]diazepin and
10,11-dihydro-dibenzo[b,f]azepin, compositions including same, methods of
their synthesis, purification and formulation and their use in prevention and
treatment of cardiac disorders, such as, but not limited to, arrhythmia and
ventricular fibrillation.

15 Sudden cardiac death is a leading cause of mortality, and ventricular
fibrillation (VF) is thought to play a major role in sudden cardiac death [1].
Ventricular fibrillation can be divided into two categories: sustained VF
(SVF), which is fatal, unless external defibrillating intervention is practiced, or
transient VF (TVF), which terminates spontaneously. Currently, only one
20 effective approach has been found to terminate SVF once SVF is initiated,
which is the application of electrical defibrillation. Electrical defibrillation can
be applied either externally or internally, by implantation. However, this
approach has a number of disadvantages. For example, electrical defibrillation
must be applied immediately to be effective, yet may not be sufficient, and
25 may even cause damage. In addition, an implanted defibrillator requires
invasive treatment. Thus, artificial defibrillation is not a cure, and does not
prevent reoccurrence of VF.

 Antiarrhythmic drugs constitute an alternative, preferable approach, as
they are aimed at preventing initiation of VF by decreasing the incidence of
30 ventricular arrhythmias that can lead to VF [2]. In addition, certain drugs, such
as bretylium, have been shown to transform SVF into TVF [3]. The

effectiveness of this treatment, however, is limited, since various mechanisms can be involved in the initiation of VF, such that antiarrhythmic drugs are unlikely to absolutely eliminate arrhythmias and totally prevent VF initiation. Furthermore, recent surveys (such as the Cardiac Arrhythmia Suppression Trial, CAST, II and I [4,5]) have clearly shown limitations to this approach. Thus, a new cardiac protective therapy is needed. For this reason, a new approach has been proposed, to use a new class of antiarrhythmic drugs [6], which can enhance spontaneous termination of VF, once it occurs. In several animal species, and even, though rarely, in humans, VF can revert spontaneously into sinus rhythm, resulting in the non-fatal TVF. It has been previously found that several factors contribute to the ability to self-defibrillate. For example, self-defibrillation is a normal feature of young mammals, but this ability decreases with age [7]. Such spontaneous defibrillation requires a relatively high degree of intercellular synchronization [8], and is enhanced by increased sympathetic activity. Thus, treatments with compounds that elevate extraneuronal catecholamine levels in the heart enhance self-defibrillation and administration of β -adrenergic blockers abolishes this activity [9].

In order to design and synthesize new, more potent and selective defibrillatory drugs, it has been found that certain dibenzoazepins (imipramine, desipramine, maprotiline and bonnacore) and phenothiazins (chlopromazin, moricizine and trifluoperazin), induce self-defibrillation and increase the threshold for electrical fibrillation [10, 11]. Moreover, tricyclic antidepressants, in addition to their antiarrhythmic and defibrillating effects, have the ability to decrease the ischemic area in the heart following coronary occlusion [12]. However, these cardio-protective effects of the compounds were expressed when relatively high doses were used, resulting in a low therapeutic index.


There is thus a need for, and it would be useful to have, pharmaceutically effective compounds which are safe and useful for the

treatment of ventricular fibrillation, particularly for the induction of TVF once SVF has been initiated, and for both treating and preventing pathological conditions associated with VF.

5 SUMMARY OF THE INVENTION

The present invention relates to 5(N-acyl)-derivatives and 5(N- β -aminoalcohol)-derivatives of 11-Oxo-10,11-dihydro-dibenzo [b,e][1,4] diazepin and 10,11-dihydro-dibenzo[b,f]azepin, compositions including same, methods of their synthesis, purification and formulation and their use in
10 prevention and treatment of cardiac disorders. It is shown herein for the first time that these new tricyclic compounds and some previously known tricyclic compounds have been synthesized and have been shown to have substantial activity as chemical defibrillating agents.

According to the present invention, there is provided a compound
15 having a general formula (I):



wherein A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched
20 alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nC*HOHCH₂NR'R'' (the chiral C, which is marked by * can be the R anantiomer, the S anatiomer, be in a racemic mixture or in any other ratio between the R and S anantiomers), wherein *n* is
25 an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts

thereof.

Preferably, R_1 is selected from the group consisting of β -amino-alcohol, $C(=O)(CH_2)_nNR'R''$ and $(CH_2)_nCHOHCH_2NR'R''$ wherein n is an integer and further wherein the chiral carbon atom can be the R or S anantiomer, a racemic mixture thereof or a mixture of any ratio thereof; and R' , R'' are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl; and pharmaceutically acceptable salts thereof. Examples of suitable alkyl moieties include but are not limited to *iso*-propyl, *iso*-butyl, *tert*-butyl and *sec*-butyl. Most preferably, R'' is *iso*-propyl.

According to a preferred embodiment of the present invention, A and B are each an alkyl chain, more preferably a CH moiety, R_2 , R_3 , R_4 and R_5 are each hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$ and $(CH_2)_nCHOHCH_2NR'R''$, n being 0-5. Preferably, R and R' are each hydrogen and R'' is selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl and *tert*-butyl.

According to a preferred embodiment of the present invention A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R , R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$ and $(CH_2)_nCHOHCH_2NR'R''$, n being 0-5.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention relates to a group of compounds, based upon the general backbone structure of tricyclic antidepressants, namely, 11-oxo-dibenzodiazepins and dibenzoazepins N -substituted at the 5 position, as well as to pharmaceutical compositions of these compounds and to their use in the treatment and prevention of ventricular fibrillation and ischemic damage by local or systemic application. More specifically, these compounds are demonstrated to have a defibrillating effect on ventricular fibrillation, once it actually occurs.


Previous studies, aimed at characterizing the structure-activity relationships of dibenzoazepins and phenothiazines accountable to improved defibrillating activity, have indicated the relevance of several structural features of the backbone of these molecules for their efficacy against ventricular fibrillation. First, activity of the tricyclic compounds correlated with higher (more bent) dihedral angle between the two benzo rings in the tricyclic skeleton. This angle is also considered to play a detrimental role in the type of central nervous system activity of these compounds, as well as their different selectivity towards catecholamine reuptake systems (such as noradrenaline, serotonin and dopamine). Second, compounds with 5-N-substituted secondary aminoalkyl side chains (such as desipramine) exhibit higher defibrillatory activity, as opposed to tertiary alkylamine (such as in imipramine) and lastly, transition from aminoalkyl to aminoacyl in the side chain at position 10 of the phenothiazine tricyclic nucleus results in an increase in antiarrhythmic activity and decrease in psychotropic activity [10].

The development of the disclosed class of tricyclic compounds was based on the rationalized design of new compounds, aimed at more focused and selective activity as chemical defibrillators, as well as identifying additional molecules which are able to overcome shortcomings of the presently utilized approaches (electrical defibrillation, antiarrhythmic drugs, described above), and which are able to convert the fatal sustained ventricular fibrillation to the non-fatal transient one.

The experiments described below in the Examples section demonstrate that the disclosed compounds are indeed effective in transforming the potentially fatal VF type, SVF, to the spontaneously-defibrillating type, TVF. In addition, the preferred structure is indicated in terms of a structure-activity-relationship, indicating the importance of certain structural elements in obtaining potent, selective therapeutic activity, and minimizing untoward side effects. Thus, a compound according to the present invention includes derivatives of 5-(N-alkyl), 5-(N-acyl) and 5-(N- β -aminoalcohol) dibenzoazepins of the

6

general formula (II):




[II]

wherein R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, $C(=O)(CH_2)_nNR'R''$ or $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

Preferably, R_1 is selected from the group consisting of β -amino-alcohol, $C(=O)(CH_2)_nNR'R''$, and $(CH_2)_nCHOHCH_2NR'R''$ wherein n is an integer and R' , R'' are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl; and pharmaceutically acceptable salts thereof. Examples of suitable alkyl moieties include but are not limited to *iso*-propyl, *iso*-butyl, *tert*-butyl and *sec*-butyl. Most preferably, R'' is *iso*-propyl. Also most preferably, R_Q and R_T are each a hydrogen, and q and t are each 4.

The compounds of the present invention are also useful as an active ingredient in a composition for treating or preventing a cardiac disorder, such as ventricular fibrillation, featuring a pharmaceutically effective amount of a tricyclic compound in combination with a pharmaceutically acceptable carrier, in which the tricyclic compound is of a general formula (I):



wherein A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

Preferably, R₁ is selected from the group consisting of β-amino-alcohol, C(=O)(CH₂)_nNR'R'', and (CH₂)_nCHOHCH₂NR'R'' wherein *n* is an integer and R', R'' are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl; and pharmaceutically acceptable salts thereof. Examples of suitable alkyl moieties include but are not limited to *iso*-propyl, *iso*-butyl, *tert*-butyl and *sec*-butyl. Most preferably, R'' is *iso*-propyl.

According to a preferred embodiment of the present invention, A and B are each an alkyl chain, more preferably a CH moiety, R₂, R₃, R₄ and R₅ are each hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'' and (CH₂)_nCHOHCH₂NR'R'', *n* being 0-5. Preferably, R and R' are each hydrogen and R'' is selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl and *tert*-butyl.

According to a preferred embodiment of the present invention A is CR₂R₃ or C=O and B is CR₄R₅; R, R₂, R₃, R₄, R₅ and R₆ are each a hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'' and (CH₂)_nCHOHCH₂NR'R'', *n* being 0-5. More preferably, *n* is 1 or 2.

Hereinafter, the term "tricyclic compound" refers to 5-(N-acyl) or 5-(N-alkylβaminoalcohol)-derivatives or 5-(N-alkyl)-derivatives of

10,11-dihydro-dibenzo[b,f]azepin or 5-(N-acyl) or
5-(N-alkylβaminoalcohol)-derivatives or 5-(N-alkyl)- derivatives of
11-Oxo-10,11-dihydro-dibenzo[b,e][1,4] diazepin compounds of the present
invention.

5 Hereinafter, the term "derivative" refers to the result of a chemically
altering, modifying or changing a molecule or a portion thereof, such that the
molecule either maintains or increases its functionality.

Hereinafter, the term "pharmaceutically acceptable carrier" refers to a
carrier or a diluent that does not cause significant irritation to an organism and
10 does not abrogate the biological activity and properties of the administered
compound.


Hereinafter, the term "pharmaceutically effective amount" refers to that
amount of the compound being administered which will relieve to some extent
one or more of the symptoms of the disorder being treated.

15 The composition of the present invention may be optionally and
preferably designed for topical application such as a slow release or
transdermal patch of the tricyclic compound. The composition for slow
release includes particles including a slow release carrier (typically, a
polymeric carrier), and the tricyclic compound. Slow release biodegradable
20 carriers are well known in the art. These are materials that may form particles
that may capture therein an active compound(s) and slowly degrade/dissolve
under a suitable environment (e.g., aqueous, acidic, basic, etc.) and thereby
degrade/dissolve in body fluids and release the active compound(s) therein.

Specifically, a slow release formulation or a transdermal patch of the
25 tricyclic compound can be used in patients prone to cardiac disorders, such as
arrhythmias, or with a known history of arrhythmic or fibrillatory episodes.

One particularly preferred embodiment of the present invention is
parenteral administration of the tricyclic compound, for example
intravenously. Further according to the present invention there is provided a
30 method for treating or preventing a cardiac disorder, such as ventricular

fibrillation, in a subject, by administering a pharmaceutically effective amount of a tricyclic compound of a general formula (I):



- wherein A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer;
- R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.
- Preferably, R₁ is selected from the group consisting of β-amino-alcohol, C(=O)(CH₂)_nNR'R'', and (CH₂)_nCHOHCH₂NR'R'' wherein *n* is an integer and R', R'' are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl; and pharmaceutically acceptable salts thereof. Examples of suitable alkyl moieties include but are not limited to *iso*-propyl, *iso*-butyl, *tert*-butyl and *sec*-butyl. Most preferably, R'' is *iso*-propyl.

According to a preferred embodiment of the present invention, A and B are each an alkyl chain, more preferably a CH moiety, R₂, R₃, R₄ and R₅ are each hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'' and (CH₂)_nCHOHCH₂NR'R'', *n* being 0-5. Preferably, *n* is 1 or 2. Preferably, R and R' are each hydrogen and R'' is selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl and *tert*-butyl.

According to a preferred embodiment of the present invention A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R , R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$ and $(CH_2)_nCHOHCH_2NR'R''$, n being 0-5.

Preferably, this method of treatment with the compositions of the
5 present invention is used as an adjunct or additive therapy for patients with implanted defibrillators, in order to combine the electrical defibrillation with the chemical defibrillation. The utility of such a combination has been previously shown [M.T. Neuman, *PhD Thesis*, 1995, Tel Aviv University, Tel Aviv, Israel].

10 Herein, the term "treating" includes substantially inhibiting or completely stopping episodes of cardiac dysfunction, such as ventricular fibrillation, in a subject.

Herein, the term "preventing" refers to a method for barring a subject from exhibiting symptoms of a cardiac disorder, such as ventricular
15 fibrillation, or alternatively for at least reducing the likelihood and/or severity of such symptoms arising in the subject.

Further according to the present invention there is provided a method of locally treating a disorder of a tissue of a subject comprising the step of locally applying the herein above described composition to the tissue. The method includes the steps of
20 applying the composition to an implant and inserting the implant into a tissue, such as cardiac tissue. Alternatively, the composition can be applied to a transdermal patch, which is applied to the skin for system absorption.

Also according to the present invention, there is provided a method for preventing ischemia in the cardiac tissue of a subject, by administering the
25 above-referenced compound of the present invention to the subject.

A precise understanding of the mechanism by which the tricyclic compounds of the present invention cause such chemical defibrillation is not required in order to practice the present invention. However, while not wishing to be bound to any particular mechanism or theory, it is believed that increased
30 catecholamine levels, induced by the compounds of the present invention, are

involved in the process. Several lines of evidence support this hypothesis. For example, the evaluation of intra- and inter-species differences for the ability to defibrillate spontaneously have indicated the central role of cardiac autoregulation. In particular, TVF appears in animals with predominantly sympathetic autoregulation, while SVF appears in animals with predominantly vagal autoregulation. Within members of the same species, the ability to defibrillate spontaneously is a normal feature of young mammals, and this ability decreases with age. Respectively, cardiac autoregulation in young mammals is dominantly sympathetic and turns to a vagal predominance with age.

Furthermore, administration of either β -adrenergic blockers (e.g., propranolol or pindolol) or a parasympathomimetic agonist (e.g., acetylcholine or metacholine) in mammals exhibiting TVF, prolongs the duration of TVF and even transforms it into SVF. Lastly, self-defibrillation requires a relatively high degree of intercellular synchronization, which may be enhanced by elevated catecholamine levels. Thus, compounds which are known to elevate extraneuronal catecholamine levels in the heart, such as dibenzoazepins and phenothiazines, were identified to enhance ventricular self-defibrillation, an effect abolished by co-administration of β -adrenergic blockers [9, 14].

Furthermore, in a recent publication, the efficacy in defibrillating activity of dibenzoazepins and phenothiazines was directly related to their ability to inhibit noradrenaline uptake [10]. Alternatively, the compound, 11-Oxo-10,11-dihydro-5-(N-methyl)-propylaminodibenzo[b,e] [1,4]-diazepin, was previously suggested for application as a muscarinic receptor antagonist in PCT Application No. WO 91/10654], supporting the role of sympathetic predominance in potential defibrillating activity.

Thus, further according to the present invention there is provided a method of treating or preventing a cardiac disorder in a subject, by inducing cardiac sympathetic activity by administering the tricyclic compounds of the present invention as hereinabove described.

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions illustrate the invention in a non-limiting fashion. The following protocols and experimental details are referenced in the Examples that follow.


Example 1

Synthesis of 10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl]

5-H-dibenzo[b,f]azepin monohydrochloride compounds

Synthesis of 10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5H-dibenzo[b,f]azepin: The synthesis was performed as known in the literature (Schindler W.; Hafliger F.; *Helvetica Chimica Acta* 1954, **59**, 472-483). To a solution of 5H-10,11-dihydro-dibenzo[b,f] azepin (0.85 gr., 4.359 mmol) in benzene (50 ml), 0.5 ml 3-chloropropionyl chloride (5.225 mmol) was added dropwise. The mixture was refluxed for 3 h, the solvent was removed under reduced pressure and the residue was washed with 5 % aq. HCl, followed by extraction with CH₂Cl₂ (20 ml). The resulting organic layer was dried over Na₂SO₄, and the crude product was purified by flash chromatography (silica gel, hexane-ethyl acetate 8:2), resulting in 1.133 gr. (91 % yield) of 10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5-H-dibenzo[b,f]azepin, in the form of white crystals. NMR (CDCl₃): 7.16 (bs, 8H), 3.82 (m, 2H), 3.46 (m, 1H), 2.85 (m, 2H), 2.51 (m, 1H). MS (CI): 286 (M⁺).

Scheme 1 below illustrates the synthesis and structure of 10,11 dihydro-5-[(3-chloro)1-oxopropyl] 5-H-dibenzo[b,f]azepin:




Synthesis of 10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl]-5-H-dibenzo[b,f]azepin monohydrochloride:

Synthesis of 10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl]-5-H-dibenzo[b,f]azepin derivatives was achieved by reaction of the 10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5-H-dibenzo[b,f]azepin as a starting material with the corresponding alkyl amine. The succeeding derivatives, wherein the 3-N- substituted alkyl is a methyl, an ethyl or an iso-propyl, (compounds 15a-c) were prepared following the below-described general procedure: A well-stirred suspension of 10,11-dihydro-5-[(3-chloro)-1-oxopropyl]-5-H-dibenzo [b,f]azepin (1.71 gr., 6.0 mmol) in ethanol (50 ml) was warmed to 65 °C. Alkylamine (10 mmol) was added dropwise. The mixture was stirred for 1 h at 65 °C, and then allowed to cool to room temperature. The mixture was washed with 5 % aq. potassium bicarbonate and extracted with CH₂Cl₂ (20 ml). The organic layer was dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude product was recrystallized from EtOAc at 0 °C. The precipitate was filtered to result in the appropriate free base. The solid was then dissolved in toluene and HCl was bubbled till a precipitate formed. The precipitate was filtered and dried under reduced pressure resulting in the appropriate monohydrochloride salt. Alternatively, wherein bulkier alkyl groups were used for substituting the 3-N alkyl, such as *tert*-butyl, sec-butyl, iso-butyl and benzyl (compounds 15d-g), the following procedure was used: A solution of 10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5-H-dibenzo[b,f] azepin (0.285 gr., 1.0 mmol) in *iso*-propanol (15 ml) and monoamine (15 ml) was refluxed overnight. The solvent was removed under reduced pressure, and the

crude product was recrystallized from EtOAc at 0 °C. The solid was dissolved in toluene and HCl was bubbled till a precipitate was formed. The precipitate was filtered and dried under reduced pressure resulting in the appropriate monohydrochloride salt.

Scheme 2 below illustrates the synthesis and general structure of 10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl]-5-H-dibenzo[b,f]azepin monohydrochloride of both synthetic routes:



SCHEME 2 (15)


10

(i) 10,11-dihydro-5-[(3-N-methyl)-1-oxopropyl]-5-H-dibenzo

[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 1.126 gr. (67 % yield) of light yellow solid was obtained. ¹H NMR (D₂O): δ 6.87 (brm, 8H), 3.15 (s, 1H), 2.82 (brm, 4H), 2.47 (s, 3H), 2.24 (brm, 3H). FAB/MS 281 (M⁺).

15

Scheme 3 below illustrates the structure of 10,11-dihydro-5-[(3-N-methyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:



20

SCHEME 3 (15 a)


25

(ii) 10,11-dihydro-5-[(3-N-ethyl)1-oxopropyl]5-H-dibenzo[b,f]

azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 1.129 gr. (64 % yield) of light yellow solid was obtained. ¹H NMR (D₂O): δ 6.89 (brm, 8H), 3.12 (s, 1H), 2.84 (brm, 7H), 2.27

(brm, 2H), 1.02 (t, J=7.4, 3H). FAB/MS 295 (M^+).


Scheme 4 below illustrates the structure of 10,11-dihydro-5-[(3-N-ethyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:



SCHEME 4 (15 b)

(iii) 10,11-dihydro-5-[(3-N-iso-propyl)1-oxopropyl]5-H-dibenzo[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 1.219 gr. (66 % yield) of light yellow solid was obtained, with mp 199.1 °C. ^1H NMR (D_2O): δ 6.97 (brm, 8H), 3.14 (m, 1H), 2.97 (m, 4H), 2.67 (m, 1H), 2.42 (m, 1H), 2.38 (m, 2H), 1.08 (d, J=6.6, 6H). FAB/MS 309 (M^+).

Scheme 5 below illustrates the structure of 10,11-dihydro-5-[(3-N-iso-propyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:




SCHEME 5 (15 c)

(iv) 10,11-dihydro-5-[(3-N-tert-butyl)1-oxopropyl]5-H-dibenzo[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 280 mgr. (87 % yield) was obtained. ^1H NMR (CDCl_3): δ 7.24 (m, 8H), 3.39 (m, 2H), 2.85 (m, 5H), 2.51 (m, 1H), 1.26 (m, 9H). FAB/MS 323 (M^+).

Scheme 6 below illustrates the structure of 10,11-dihydro-5-[(3-N-tert-butyl)1-oxopropyl]5-H-dibenzo[b,f]azepin monohydrochloride:

16




SCHEME 6 (15 d)

(v) 10,11-dihydro-5-[(3-N-*sect*-butyl)1-oxopropyl]5-H-dibenzo

[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 241 mg. (75 % yield) was obtained. ¹H NMR (CDCl₃): δ 7.25 (m, 8H), 3.37 (m, 2H), 2.97 (m, 5H), 2.79 (m, 2H), 1.52 (m, 2H), 0.99 (m, 6H). FAB/MS 323 (M⁺).

Scheme 7 below illustrates the structure of 10,11-dihydro-5-[(3-N-*sect*-butyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:




SCHEME 7 (15 e)

(vi) 10,11-dihydro-5-[(3-N-*iso*-butyl)1-oxopropyl]5-H-dibenzo

[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 264 mg. (82 % yield) was obtained. ¹H NMR (CDCl₃): δ 7.23 (m, 8H), 3.35 (m, 2H), 2.82 (m, 4H), 2.47 (m, 2H), 1.84 (m, 1H), 0.95 (d, J=6.6 Hz, 3H), 0.89 (d, J=6.6 Hz, 3H). FAB/MS 323 (M⁺).


Scheme 8 below illustrates the structure of 10,11-dihydro-5- [(3-N-*iso*-butyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:

**SCHEME 8 (15 f)**


(vii) 10,11-dihydro-5-[(3-N-benzyl)1-oxopropyl]5-H-dibenzo

[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 367 mg. (67 % yield) was obtained. ¹H NMR (CDCl₃): δ 7.23 (m, 8H), 3.35 (m, 2H), 2.82 (m, 4H), 2.47 (m, 2H), 1.84 (m, 1H), 0.95 (d, J=6.6 Hz., 3H), 0.89 (d, J=6.6 Hz, 3H). FAB/MS 357 (M⁺).

Scheme 9 below illustrates the structure of 10,11-dihydro-5- [(3-N-benzyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:

**SCHEME 9 (15 g)**


Scheme 9a describes the synthesis of the β-amino alcohol derivative according to the present invention, which was performed in two stages.

**SCHEME 9a**

10,11-dihydro-5-[N-2 methyloxirane]5-H-dibenzo[b,f]azepin (20).

20r, 20s (Stage I):

To a solution of 5H-10,11-dihydro-dibenzo[b,f] azepin (1.320 g, 6.711 mmol, see Scheme 1, above) in benzene (50 ml) was added NaNH₂ (0.5 gr). The mixture was refluxed for 2 hr and epichlorohydrin (1 ml, 12.810 mmol) was added dropwise. The mixture was refluxed for 6 hr. The solvent was removed under reduced pressure, and the residue was washed with 5% aq HCl, and extracted with CH₂Cl₂ (20 ml). The organic layer was dried over Na₂SO₄ and the crude product was purified by flash chromatography (silica gel, hexane-ethyl acetate 9.5:0.5) to give 20, (0.75 g, 45%) in the form of white powder. ¹H NMR (chloroform): 7.07 (bs, 4H), 6.93 (m, 2H), 6.73 (bt, 2H) 3.91 (m, 2H), 3.16 (m, 4H), 3.05 (m, 1H), 2.67 (d, 1H), 2.55 (d, 1H). MS (CI): 251 (M⁺). (Scheme 9b)



SCHEME 9b

10,11-dihydro-5-[N-β iso-propylamino-2propanol][5-H-dibenzo[b,f]azepin monohydrochloride, 25 bi, 25 bis, 25 bir (Stage II)

General procedure: A suspension of 20 (1.5 g, 5.0 mmol) in *iso*-propanol (50 ml) was warmed to 30 °C, *iso*-propyl amine (10 mmol) was added dropwise, the mixture was stirred overnight at this temperature and then allowed to cool to room temperature. The solvent was removed under reduced pressure, and the crude product was recrystallized from ethyl acetate at 0 °C. The precipitation was filtered to give the appropriate free base. The solid was dissolved in toluene and HCl was bubbled until a precipitate reappeared. The precipitation was filtered and dried under reduced pressure to give 25 bi salt.


¹H NMR (chloroform): 7.07 (bs, 4H), 6.93 (m, 2H), 6.73 (bt, 2H) 3.79 (m, 1H), 3.15 (s, 4H), 2.78 (m, 1H), 2.72 (d, 2H), 2.55 (d, 2H), 1.01 (d, 6H). MS (CI): 311 (M⁺).

Example 2

Synthesis of 11-Oxo-10,11-dihydro-5-[(N-alkyl)1-oxopropyl]-5-H-dibenzo[b,e][1,4]diazepin monohydrochloride compounds

Synthesis of 11 - Oxo - 10, 11 - dihydro - 5H - dibenzo [b,e] [1,4] diazepin: The synthesis was performed according to the below synthetic scheme. A suspension of 2-chlorobenzoic acid (5.08 gr., 31.81 mmol), o-phenylenediamine (3.46 gr., 31.48 mmol), copper powder (2.14 gr., 31.7 mmol) and molecular sieves (3A) in chlorobenzene (100 ml) was vigorously stirred at 130 °C for 8 h. The hot mixture was rapidly filtered and the filtrate was concentrated under reduced pressure. The solid precipitate was collected by filtration and then recrystallized from EtOH resulting in 11-Oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin 5.48 gr. (82 % yield) in the form of bright yellow powder. ¹H NMR (acetone): 8.89 (s, 1H), 7.80 (d, J=7.7 Hz., 1H), 7.33 (t, J=7.3 Hz., 1H), 7.07 (m, 6H). FAB/MS: 211 (M⁺).

Scheme 10 below illustrates the synthesis and structure of 11-Oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin monohydrochloride:




SCHEME 10 (1)

Synthesis of 11-Oxo-10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5-H-dibenzo[b,e] [1,4]diazepin:

The synthesis was performed according to the below synthetic scheme. To a solution of 11-Oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin (0.376 gr., 1.79 mmol) in dry

THF, (10 ml) NaNH₂ (0.132 gr., 3.39 mmol) was added. The mixture was cooled to 0 °C, and 0.2 ml 3-chloropropionyl chloride (2.09 mmol) was added dropwise. The mixture was stirred for 30 min at 0 °C, allowed warming to room temperature, washed with 5 % aq. potassium bicarbonate and extracted with CH₂Cl₂ (20 ml). The resulting organic layer was dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude product was crystallized from ether, resulting in 0.467 gr. (87 % yield) of 11-Oxo-10,11 -dihydro-5-[(3-chloro)1-oxopropyl] 5-H-dibenzo[b,e] [1,4]diazepin in the form of a yellow solid, mp 241-242 °C. ¹H NMR (CDCl₃): 8.78 (s, 1H), 7.98 (s, 1H), 7.59 (s, 1H), 7.4-7.26 (m, 6H), 3.77 (m, 4H). FAB/MS: 301 (M⁺).

Scheme 11 below illustrates the synthesis and structure of 11-Oxo-10,11-dihydro-5-[(3-chloro)1-oxopropyl] 5-H-dibenzo[b,e] [1,4] diazepin :




SCHEME 11 (6)

Synthesis of 11-Oxo-10,11-dihydro-5-[(N-alkyl)1-oxopropyl]5-H-dibenzo[b,e] [1,4]diazepin monohydrochloride: The synthesis of the below described 11-Oxo-10,11-dihydro-5-[(N-alkyl)1-oxopropyl]5-H- dibenzo [b,e][1,4]diazepin hydrochloride compounds, 11a-c, was performed by reacting 11-Oxo-10,11-dihydro-5-[(3-chloro)1-oxopropyl] -5-H-dibenzo[b,e][1,4]diazepin, as a starting material, with the appropriate alkyl amine. A well-stirred suspension of 11-Oxo-10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5-H-dibenzo[b,e][1,4]diazepin (1.5 gr., 5.0 mmol) in ethanol (50 ml) was warmed to 65 °C. Alkylamine (10 mmol) was added dropwise. The mixture was stirred for 1 h at 65 °C, and then allowed to cool to room temperature. The mixture was then washed with 5 / aq. potassium

bicarbonate and extracted thrice with CH_2Cl_2 (20 ml). The organic layer was dried over Na_2SO_4 , filtered and the solvent was removed under reduced pressure. The crude product was recrystallized from EtOAc at 0 °C. The precipitate was filtered to result in the appropriate free base. The solid was then dissolved in toluene and HCl was bubbled till a precipitate formed. The precipitate was filtered and dried under reduced pressure resulting in the appropriate hydrochloride salt.


Scheme 12 below illustrates the synthesis and general structure of 11-Oxo-10,11-dihydro-5-[(N-alkyl)1-oxopropyl] 5-H-dibenzo[b,e] [1,4]diazepin monohydrochloride:



SCHEME 12 (11)


(i) *Synthesis of 11-Oxo-10,11-dihydro-5-[(N-methyl)1-oxopropyl] 5-H-dibenzo[b,e] [1,4]diazepin monohydrochloride:* The synthesis was performed according to the above synthetic scheme. The compound, in the form of a light-pink solid was obtained, 627 mg. (44 % yield), with mp=223-225 °C. ^1H NMR (D_2O): δ 7.33 (br m, 8H), 3.06 (t, $J=6$ Hz, 2H), 2.9 (m, 1H), 2.48 (s, 3H), 2.36 (br m, 1H). FAB/MS 297 (M^+).

Scheme 13 below illustrates the structure of 11-Oxo-10,11-dihydro-5-[(3-N-methyl)1-oxopropyl] 5-H-dibenzo[b,e][1,4]diazepin monohydrochloride:



SCHEME 13 (11 a)

(ii) *Synthesis of 11-Oxo-10,11-dihydro-5-[(N-ethyl)1-oxopropyl]-5-H-dibenzo[b,e][1,4]diazepin monohydrochloride:* The synthesis was performed according to the above synthetic scheme. The compound, in the form of light-yellow solid, was obtained, 1.023 gr. (66 % yield), with mp 243-245 °C. ¹H NMR (D₂O): 7.40 (br m, 8H), 3.08 (t, J=6.1 Hz., 2H), 2.86 (m, 3H), 2.38 (m, 1H), 1.06 (t, J=7.3, 3H). FAB/MS: 311 (m⁺). Scheme 14 below illustrates the structure of 11-Oxo-10,11-dihydro-5-[(N-ethyl)1-oxopropyl]-5-H-dibenzo[b,e][1,4]diazepin hydrochloride:




SCHEME 14 (11 b)

(iii) *Synthesis of 11-Oxo-10,11-dihydro-5-[(N-iso-propyl)-1-oxopropyl]-5-H-dibenzo[b,e][1,4]diazepin monohydrochloride:* The synthesis was performed according to the above synthetic scheme. The compound, in the form of light-orange solid, was obtained, 791 mgr. (49 % yield). ¹H NMR (D₂O): 7.35 (br m, 8H), 3.05 (br m., 3H), 2.85 (m, 1H), 2.33

23

(m, 1H), 1.08 (t, J=7.3, 3H). FAB/MS: 323 (m^+).

Scheme 14 below illustrates the structure of 11-Oxo-10,11-dihydro -5 - [(N-*iso*-propyl) 1 - oxopropyl] 5 - H - dibenzo [b,e] [1,4] diazepin monohydrochloride:



SCHEME 15(11 c)

10

Example 3

Synthesis of 10,11-dihydro-5-[N-β isopropylamino- 2propanol] 5-H-dibenzo [b,f]azepin (25bi). 25bir, 25bis monohydrochloride compounds


10,11-dihydro-5-[N-2 methyloxirane]5-H-dibenzo[b,f]azepin (20).

20r, 20s: To a solution of **5** (1.320 g, 6.711 mmol) in benzene (50 mL) was added NaNH₂ (0.5 gr). The mixture was refluxed for 2 hr and the appropriate epichlorohydrin (1 mL, 12.810 mmol) was added dropwise (racemic to obtain **20**, R enantiomer to obtain **20r** and S enantiomer to obtain **20s**. The mixture was refluxed for 6 hrs. The solvent was removed under reduced pressure, and the residue was washed with 5% aq HCl, and extracted with CH₂Cl₂ (2 x 20 mL). The organic layer was dried over Na₂SO₄ and the crude product was purified by flash chromatography (silica gel, hexane-ethyl acetate 9.5:0.5) to give **20**, (0.75 g, 45%) in the form of white powder. ¹H NMR (chloroform): 7.07 (bs, 4H), 6.93 (m, 2H), 6.73 (bt, 2H) 3.91 (m, 2H), 3.16 (m, 4H), 3.05 (m, 1H), 2.67 (d, 1H), 2.55 (d, 1H). MS (CI): 251 (M⁺).

25

Scheme 16 below illustrates the synthesis and structure of 10,11-dihydro- 5-[N-2 methyloxirane]5-H-dibenzo[b,f]azepin (**20**). **20r**, **20s**

24



SCHEME 16(20, 20r, 20s)


5 10,11-dihydro-5-[N- β isopropylamino-2propanol)] 5-H-dibenzo
[b,f]azepin monohydrochloride, 25 bi, 25 bis, 25 bir:

General procedure: A suspension of 20 (1.5 g, 5.0 mmol) in *iso*-propanol (50 ml) was warmed to 30 °C, *iso*-propylamine (10 mmol) was added dropwise, the mixture was stirred overnight at this temperature and then allowed to cool to room temperature. The solvent was removed under reduced
 10 pressure, and the crude product was recrystallized from ethyl acetate at 0 °C.

The precipitation was filtered to give the appropriate free base. The solid was dissolved in toluene and HCl was bubbled until a precipitation reappeared. The precipitation was filtered and dried under reduced pressure to give 25 bi salt. ¹H NMR (chloroform): 7.07 (bs, 4H), 6.93 (m, 2H), 6.73 (bt, 2H) 3.79 (m, 1H), 3.15 (s, 4H), 2.78 (m, 1H), 2.72 (d, 2H), 2.55 (d, 2H), 1.01
 15 (d, 6H). MS (CI): 311 (M⁺).

Scheme 17 below illustrates the synthesis and structure of 10,11-dihydro-5-[N- β isopropylamino-2propanol)]5-H-dibenzo[b,f]azepin monohydrochloride, 25 bi, 25 bis and 25 bir.

25



SCHEME 17(25bi, 25bir, 25bis)

Example 4

5 Antiarrhythmic defibrillating activity of
 tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin compounds

10 10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin
 monohydrochloride, 10,11-dihydro-5-[N-? isopropylamino-2propanol)]
 5-Hdibenzo [b,f]azepin monohydrochloride and 11-Oxo-10,11- dihydro – 5 -
 [(N-alkyl)1 - oxopropyl] – 5 - H-dibenzo [b,e] [1,4] diazepin hydrochloride
 were synthesized as is described hereinabove and tested for their effectiveness
 in transforming SVF to TVF, as described herein. The desired outcome was
 determined to be the ability of the drug molecule to reduce or abolish the
 occurrence of artificially induced SVF, and its transformation to the
 spontaneously defibrillating TVF. The experimental method was as follows.

15 Hydrochloride salts of the compounds were dissolved in saline.
 Activity of each compound was tested in cats of both sexes. Cats were
 anesthetized with 15-25 mg/kg intravenous sodium pentobarbital. The tested
 compounds were injected intravenously (1-3 mg/kg). The heart of each
 experimental subject was exposed through midline thoracotomy, and a room
 air respirator was applied through a tracheal cannula. Lead II
 electrocardiogram and intra-arterial blood pressure was recorded on a Grass

Polygraph (Grass Instrument Co., Quincy, MA, USA).

Fibrillating stimuli (a train of rectangular pulses of 2 to 15 V, 100 pulses/sec and duration of 0.1 to 1.0 msec, for a period of 1 sec) were delivered through two silver needle electrodes attached to the pericardium on the left ventricle. Fibrillating stimuli were one and a half to twice the strength of the fibrillating threshold.

Animals were designated as having SVF of VF failed to terminate spontaneously within 90 sec, and required electrical defibrillation. Animals that exhibited two to five consecutive episodes of VF of short (20 to 60 sec) duration were designated as having TVF. VF was induced before and after drug administration, according to a previously described procedure [13]. The type of VF was examined before and 2 to 3 min after drug treatment. Each cat served as its own control. In some experiments, a β -adrenergic blocker (propranolol, 0.1-0.6 mg/kg) was administered after drug administration, in order to evaluate the neutralizing effect of the blocker on the compound-induced catecholamine levels. Table 1 below presents the results.

TABLE 1

Compound	Relative activity in dosage of 1 mg/kg	Relative activity in dosage of 2 mg/kg	Relative activity in dosage of 3 mg/kg
15a	50%	67%	100%
15b	50%	75%	100%
15c	64%	67%	83%
15d	44%	67%	100%
15e	0	0	33%
15f	0	0	0
15g	0	0	0
11a	0	-	50%
11b	0	50%	50%
11c	0	0	0
25bi	100%	100%	-
25bir	50%	100%	-
25bis	100%	100%	-

a. TVF /VF (%)

Example 5

Suitable formulations for administration of tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin compounds

5 The tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives of the present invention, including free base or salt form, can be administered to a subject in a number of ways, which are well known in the art. Hereinafter the term "tricyclic dibenzoazepin derivatives" refers to the group of dibenzoazepin derivatives in free base form and the group of dibenzoazepin derivatives in a
10 salt form. Hereinafter the term "tricyclic dibenzodiazepin derivatives" refers to the group of dibenzodiazepin derivatives in free base form and the group of dibenzodiazepin derivatives in a salt form. Hereinafter, the term "subject" refers to the human or any lower animal to which the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is administered. For example,
15 administration may be done topically (including ophtalmically, vaginally, rectally, intranasally), orally, or parenterally, for example by intravenous bolus or drip, intraperitoneal, subcutaneous, or intramuscular (cardiac) injection.

Formulations for topical administration may include but are not limited to lotions, ointments, gels, creams, suppositories, drops, liquids, sprays,
20 transdermal patches and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. In addition to the formulations described previously, a compound of the present invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example
25 subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the preparation may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives such as sparingly soluble salts.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.

5 Formulations for parenteral administration may include but are not limited to sterile aqueous solutions, which may also contain buffers, diluents and other suitable additives.

Dosing is dependent on the severity of the symptoms of arrhythmic or fibrillating occurrence and on the responsiveness of the subject to the tricyclic dibenzoazepin derivatives. Persons of ordinary skill in the art can easily
10 determine optimum dosages, dosing methodologies and repetition rates.

Example 6

Method of treatment or prevention of ventricular fibrillation

As noted above, the compounds of the present invention, which are
15 tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives, have been shown to be effective defibrillating agents. The following example is an illustration only of a method of treating VF with the dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives, and is not intended to be limiting.

The method includes the step of administering the tricyclic
20 dibenzoazepin or 11-Oxo-dibenzodiazepin derivatives, in a pharmaceutically acceptable carrier as described in Example 3 above, to a subject to be treated. The tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is administered according to an effective dosing methodology, preferably until a predefined endpoint is reached, such as the prevention of VF occurrence or
25 abnormal cardiac activity. Optionally and preferably, the compound is administered parenterally.

According to another preferred embodiment of the present invention, the compound is used as an adjunct or additive treatment for a patient who has received an implanted defibrillator, such that the compound is administered to
30 the patient as previously described.

Example 7Method of manufacture of a medicamentcontaining a tricyclic dibenzazepin and 11-Oxo-dibenzodiazepin derivative


5 The following is an example of a method of manufacturing a tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivative. First, the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is synthesized in accordance with good pharmaceutical manufacturing practice. Examples of methods of synthesizing the tricyclic dibenzoazepin and
10 11-Oxo-dibenzodiazepin derivatives were given previously herein. Next, the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is placed in a suitable pharmaceutical carrier, as described in Example 3 above, again in accordance with good pharmaceutical manufacturing practice.

15 It will be appreciated that the above descriptions are intended only to serve as examples, and that many other embodiments are possible within the spirit and the scope of the present invention.

20 Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

WHAT IS CLAIMED IS:

1. A compound having a general formula (II):



[II]

wherein R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.


2. The compound of claim 1, wherein R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R' , R_Q , R_T , are each a hydrogen and R'' is as defined above.

3. The compound of claim 2, wherein n is 2 and R'' is an alkyl selected from the group consisting of propyl, *n*-butyl, *tert*-butyl and with the proviso that R'' is not a methyl or an ethyl moiety.

4. The compound of claim 2, wherein n is 1 or 2 and R'' is saturated or unsaturated $(CH_2)_m$ -cycloalkyl or $(CH_2)_m$ -(hetero)aryl, m being 0-5.

5. The compound of claim 4, wherein m is 1 and R'' is an aromatic 6-member ring.

6. A composition for treating or preventing a cardiac disorder, comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier selected from the group consisting of a slow release carrier, an implant and a transdermal patch, said compound being a member of a group having the formula:



wherein,

A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

7. The composition of claim 6, wherein A and B are each a carbon, R₂, R₃, R₄ and R₅ are each a hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'', *n* being 0-5, R' and R are each hydrogen and R'' is as defined above.

8. The composition of claim 7, wherein *n* is 1 or 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

9. The composition of claim 7, wherein n is 1 or 2 and R'' is saturated or unsaturated $(CH_2)_m$ -cycloalkyl or $(CH_2)_m$ -(hetero)aryl, m being 0-5.


10. The composition of claim 9, wherein m is 1 and R'' is an aromatic 6-member ring.

11. The composition of claim 6, wherein A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above.

12. The composition of claim 11, wherein n is 2 and R'' is an alkyl selected from the group consisting of ethyl, propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

13. The composition of claim 11, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

14. A method for treating or preventing a cardiac disorder in a subject, the method comprising the step of administering a pharmaceutically effective amount of a compound, said compound being a member of a group having the formula:



wherein,

A is CH , CR_2R_3 or $C=O$; B is CH , CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 ,


20. The method of claim 18, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

21. The method of claim 14, wherein the cardiac disorder is ventricular fibrillation or ischemia.

22. The method of claim 15, wherein said compound is administered to the subject parenterally.

23. The method of claim 15, wherein an implanted defibrillator is implanted in the subject, such that said compound is an adjunct treatment to defibrillation by said implanted defibrillator.

24. A method for stopping the occurrence of ventricular fibrillation in a subject, the method comprising the step of administering a pharmaceutically effective amount of a compound, said compound being a member of a group having the formula:



wherein,

A is CH , CR_2R_3 or $C=O$; B is CH , CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl; or A and B together are $C=C$; R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q ,

R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

25. The method of claim 24, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above..

26. The method of claim 25, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

27. The method of claim 25, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

28. The method of claim 24, wherein A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5 and R' is a hydrogen and R'' is as defined above.

29. The method of claim 28, wherein n is 2 and R'' is an alkyl selected from the group consisting of ethyl, propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.


30. The method of claim 28, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

31. The method of claim 24, wherein said compound is administered

to the subject parenterally.

32. The method of claim 24, wherein an implanted defibrillator is implanted in the subject, such that said compound is an adjunct treatment to defibrillation by said implanted defibrillator.

33. A method of locally treating or preventing a disorder of a tissue of a subject comprising the step of locally applying onto said tissue a composition for treating or preventing a cardiac disorder, said composition comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier, said compound being a member of a group having the formula:



wherein A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

34. The method of claim 33, wherein the step of locally applying the

unsubstituted $(\text{CH}_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

39. The method of claim 38, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, n being 0-5 and R and R' are each hydrogen and R'' is as defined above.

40. The method of claim 39, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

41. The method of claim 39, wherein n is 2 and R'' is saturated or unsaturated $(\text{CH}_2)_m$ -(hetero)aryl, m being 0-5.

42. The method of claim 38, wherein A is CR_2R_3 or $\text{C}=\text{O}$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, n being 0-5 and R' is a hydrogen and R'' is as defined above.


43. The method of claim 42, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

44. The method of claim 42, wherein n is 2 and R'' is saturated or unsaturated $(\text{CH}_2)_m$ -(hetero)aryl, m being 0-5.

45. The method of claim 38, wherein the cardiac disorder is ventricular fibrillation or ischemia.

WHAT IS CLAIMED IS:

1. A compound having a general formula (II):



wherein R_1 is an unsaturated alkyl, amino-alcohol, diamino, or cycloalkyl; R_Q and R_T are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.


2. The compound of claim 1, wherein R_1 is a said amino-alcohol being $(CH_2)_nCHOHCH_2NR'R''$, wherein n being 0-5, R' , R_Q , R_T , are each a hydrogen and R'' is a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide.

3. The compound of claim 2, wherein n is 2 and R'' is an alkyl selected from the group consisting of propyl, *n*-butyl, *tert*-butyl and with the proviso that R'' is not a methyl or an ethyl moiety.

4. The compound of claim 2, wherein n is 1 or 2 and R'' is saturated or unsaturated $(CH_2)_m$ -cycloalkyl or $(CH_2)_m$ -(hetero)aryl, m being 0-5.

5. The compound of claim 4, wherein m is 1 and R'' is an aromatic 6-member ring.

6. A composition for treating or preventing cardiac arrhythmia, comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier selected from the group consisting of a slow release carrier, an implant and a transdermal patch, said compound being a member of a group having the formula:




wherein,

A is CH or CR_2R_3 ; B is CH, CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl; or A and B together are $C=C$; R_1 is an unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

7. The composition of claim 6, wherein A and B are each a carbon, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R' and R are each hydrogen and R'' is as defined above.

8. The composition of claim 7, wherein n is 1 or 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.
9. The composition of claim 7, wherein n is 1 or 2 and R'' is saturated or unsaturated $(CH_2)_m$ -cycloalkyl or $(CH_2)_m$ -(hetero)aryl, m being 0-5.
10. The composition of claim 9, wherein m is 1 and R'' is an aromatic 6-member ring.
11. The composition of claim 6, wherein A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above.
12. The composition of claim 11, wherein n is 2 and R'' is an alkyl selected from the group consisting of ethyl, propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.
13. The composition of claim 11, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.
14. A method for treating or preventing cardiac arrhythmia in a subject, the method comprising the step of administering a pharmaceutically effective amount of a compound, said compound being a member of a group having the formula:



wherein,

A is CH or CR₂R₃; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is an unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

15. The method of claim 14, wherein A and B are each a CH moiety, R₂, R₃, R₄ and R₅ are each a hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'', *n* being 0-5, R and R' are each hydrogen and R'' is as defined above.

16. The method of claim 14, wherein *n* is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

17. The method of claim 15, wherein *n* is 2 and R'' is saturated or unsaturated (CH₂)_m-(hetero)aryl, *m* being 0-5.

18. The method of claim 14, wherein A is CR₂R₃ or C=O and B is CR₄R₅; R₂, R₃, R₄, R₅ and R₆ are each a hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'', *n* being 0-5, R and R' are each hydrogen and R'' is as defined above.

19. The method of claim 18, wherein *n* is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl

20. The method of claim 18, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

21. The method of claim 15, wherein said compound is administered to the subject parenterally.

22. The method of claim 15, wherein an implanted defibrillator is implanted in the subject, such that said compound is an adjunct treatment to defibrillation by said implanted defibrillator.

23. A method for transforming sustained ventricular fibrillation to spontaneously defibrillating transient ventricular fibrillation in a subject, the method comprising the step of administering a pharmaceutically effective amount of a compound, said compound being a member of a group having the formula:



wherein,

A is CH, CR_2R_3 or $C=O$; B is CH, CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl; or A and B together are $C=C$; R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or

branched alkyl, substituted or unsubstituted $(\text{CH}_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

24. The method of claim 23, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above..

25. The method of claim 24, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

26. The method of claim 24, wherein n is 2 and R'' is saturated or unsaturated $(\text{CH}_2)_m$ -(hetero)aryl, m being 0-5.

27. The method of claim 23, wherein A is CR_2R_3 or $\text{C}=\text{O}$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, n being 0-5 and R' is a hydrogen and R'' is as defined above.


28. The method of claim 27, wherein n is 2 and R'' is an alkyl selected from the group consisting of ethyl, propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

29. The method of claim 27, wherein n is 2 and R'' is saturated or unsaturated $(\text{CH}_2)_m$ -(hetero)aryl, m being 0-5.

30. The method of claim 23, wherein said compound is administered to the subject parenterally.

31. The method of claim 23, wherein an implanted defibrillator is implanted in the subject, such that said compound is an adjunct treatment to defibrillation by said implanted defibrillator.

32. A method of locally treating or preventing cardiac ischemia in a subject comprising the step of locally applying onto a cardiac tissue a composition comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier, said compound being a member of a group having the formula:




wherein A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

33. The method of claim 32, wherein the step of locally applying the composition onto said tissue further comprises the steps of:

- (i) applying the composition to an implant; and

- (ii) inserting said implant into said tissue.

34. A method for transforming sustained ventricular fibrillation to spontaneously defibrillating transient ventricular fibrillation in a subject, the method comprising the step of inducing cardiac sympathetic activity by administering a compound to the subject, said compound being a member of a group having the formula:



wherein,

A is CH, CR_2R_3 or $\text{C}=\text{O}$; B is CH, CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(\text{CH}_2)_m$ -(hetero)aryl; or A and B together are $\text{C}=\text{C}$; R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, $(\text{CH}_2)_n\text{CHOHCH}_2\text{NR}'\text{R}''$, wherein n is an integer; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(\text{CH}_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

35. The method of claim 34, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, n being 0-5 and R and R' are each hydrogen and R'' is as defined above.

36. The method of claim 35, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

37. The method of claim 35, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

38. The method of claim 34, wherein A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5 and R' is a hydrogen and R'' is as defined above.

39. The method of claim 38, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

40. The method of claim 38, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

Polygraph (Grass Instrument Co., Quincy, MA, USA).

Fibrillating stimuli (a train of rectangular pulses of 2 to 15 V, 100 pulses/sec and duration of 0.1 to 1.0 msec, for a period of 1 sec) were delivered through two silver needle electrodes attached to the pericardium on the left ventricle. Fibrillating stimuli were one and a half to twice the strength of the fibrillating threshold.

Animals were designated as having SVF if VF failed to terminate spontaneously within 90 sec, and required electrical defibrillation. Animals that exhibited two to five consecutive episodes of VF of short (20 to 60 sec) duration were designated as having TVF. VF was induced before and after drug administration, according to a previously described procedure [13]. The type of VF was examined before and 2 to 3 min after drug treatment. Each cat served as its own control. In some experiments, a β -adrenergic blocker (propranolol, 0.1-0.6 mg/kg) was administered after drug administration, in order to evaluate the neutralizing effect of the blocker on the compound-induced catecholamine levels. Table 1 below presents the results.

TABLE 1

Compound	Relative activity in dosage of 1 mg/kg	Relative activity in dosage of 2 mg/kg	Relative activity in dosage of 3 mg/kg
15a	50%	67%	100%
15b	50%	75%	100%
15c	64%	67%	83%
15d	44%	67%	100%
15e	0	0	33%
15f	0	0	0
15g	0	0	0
11a	0	-	50%
11b	0	50%	50%
11c	0	0	0
25bi	100%	100%	-
25bir	50%	100%	-
25bis	100%	100%	-

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.

- 5 Formulations for parenteral administration may include but are not limited to sterile aqueous solutions, which may also contain buffers, diluents and other suitable additives.

Dosing is dependent on the severity of the symptoms of arrhythmic or fibrillating occurrence and on the responsiveness of the subject to the tricyclic
10 dibenzoazepin derivatives. Persons of ordinary skill in the art can easily determine optimum dosages, dosing methodologies and repetition rates.

Example 6

Method of treatment or prevention of ventricular fibrillation

As noted above, the compounds of the present invention, which are
15 tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives, have been shown to be effective defibrillating agents. The following example is an illustration only of a method of treating VF with the dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives, and is not intended to be limiting.

The method includes the step of administering the tricyclic
20 dibenzoazepin or 11-Oxo-dibenzodiazepin derivatives, in a pharmaceutically acceptable carrier as described in Example 5 above, to a subject to be treated. The tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is administered according to an effective dosing methodology, preferably until a predefined endpoint is reached, such as the prevention of VF occurrence or
25 abnormal cardiac activity. Optionally and preferably, the compound is administered parenterally.

According to another preferred embodiment of the present invention, the compound is used as an adjunct or additive treatment for a patient who has received an implanted defibrillator, such that the compound is administered to
30 the patient as previously described.

Example 7Method of manufacture of a medicamentcontaining a tricyclic dibenzazepin and 11-Oxo-dibenzodiazepin derivative

- 5 The following is an example of a method of manufacturing a tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivative. First, the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is synthesized in accordance with good pharmaceutical manufacturing practice. Examples of methods of synthesizing the tricyclic dibenzoazepin and
- 10 11-Oxo-dibenzodiazepin derivatives were given previously herein. Next, the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is placed in a suitable pharmaceutical carrier, as described in Example 5 above, again in accordance with good pharmaceutical manufacturing practice.
- 15 It will be appreciated that the above descriptions are intended only to serve as examples, and that many other embodiments are possible within the spirit and the scope of the present invention.

- 20 Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

LIST OF REFERENCES CITED

1. Olshausen K.V., Witt T., Pop T., Treese N., Bethge K., Meyer J. Sudden cardiac death while wearing a Holter monitor. *Am. J. Cardiol.*, 67: 381-386, 1991.
2. Vaughan Williams E.M. Classification of antiarrhythmic drugs. In: Sandoe E., Flasted-Jansen E. Olesen K.H., eds. *Symposium on Cardiac Arrhythmias*. Sudertalje Seden: AB Astra, pp. 449-472, 1970.
3. Sanna G., Archidiacono R. Chemical ventricular defibrillation of the human heart with bretylium tosylate. *Am. J. Cardiol.* 32: 982-986, 1973.
4. CAST Investigators. Preliminary report: Effect of ecainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. *N. Engl. J. Med.* 321: 406-412, 1989.
5. CAST II Investigators - Effect of the antiarrhythmic agent moricizine on after myocardial infarction. *N. Engl. J. Med.* 327: 227-233, 1992.
6. Manoach M., Varon D., Neuman M., Erez M. Editorial – A new group of defibrillatory drugs in the classification of antiarrhythmic agents. *Int. J. Cardiol.* 21: 211-217, 1988.
7. Manoach M., Varon D., Erez M. The role of catecholamines on intracellular coupling, myocardial cell synchronization and self ventricular defibrillation. *Mol. Cell. Biochem.* 147: 181-185, 1995.
8. Manoach M., Erez M., Varon D. Properties required for self ventricular defibrillation: Influence of age and drugs. *Cardiol. Elderly.* 1: 337-344, 1993.
9. Manoach M., Beker B., Erez M., Varon D., Netz H. Spontaneous termination of electrically induced ventricular fibrillation. In: Macfarlane P.W. ed. *Progress in Electrophysiology*. London: Pitman Medical Publications Ltd, pp. 361-365, 1979.
10. Erez M., Varon D. Dibenzazepines and phenothiazines – A winding path to defibrillatory antiarrhythmic agents. *Exp. Clin. Cardiol.* 2: 59-63, 1997.
11. Kaverina N.V., Skoldinov A.P. New cardiovascular drugs among

TRICYCLIC COMPOUNDS AND THEIR USES AS ANTIARRHYTHMIC ANTIFIBRILLATORY AND DEFIBRILLATORY AGENTS

FIELD AND BACKGROUND OF THE INVENTION

5 The present invention relates to tricyclic compounds of the 11-oxo-dibenzodiazepin and dibenzoazepin families, and their new therapeutic uses as defibrillating, and/or anti-fibrillatory, and/or anti-arrhythmic and/or anti-ischemic drugs. More particularly, the present invention relates to 5(N-acyl)-derivatives and 5(N- β -aminoalcohol)-derivatives of
10 11-Oxo-10,11-dihydro-dibenzo[b,e] [1,4]diazepin and 10,11-dihydro-dibenzo[b,f]azepin, compositions including same, methods of their synthesis, purification and formulation and their use in prevention and treatment of cardiac disorders, such as, but not limited to, arrhythmia and ventricular fibrillation.

15 Sudden cardiac death is a leading cause of mortality, and ventricular fibrillation (VF) is thought to play a major role in sudden cardiac death [1]. Ventricular fibrillation can be divided into two categories: sustained VF (SVF), which is fatal, unless external defibrillating intervention is practiced, or transient VF (TVF), which terminates spontaneously. Currently, only one
20 effective approach has been found to terminate SVF once SVF is initiated, which is the application of electrical defibrillation. Electrical defibrillation can be applied either externally or internally, by implantation. However, this approach has a number of disadvantages. For example, electrical defibrillation must be applied immediately to be effective, yet may not be sufficient, and
25 may even cause damage. In addition, an implanted defibrillator requires invasive treatment. Thus, artificial defibrillation is not a cure, and does not prevent reoccurrence of VF.

 Antiarrhythmic drugs constitute an alternative, preferable approach, as they are aimed at preventing initiation of VF by decreasing the incidence of
30 ventricular arrhythmias that can lead to VF [2]. In addition, certain drugs, such as bretylium, have been shown to transform SVF into TVF [3]. The

effectiveness of this treatment, however, is limited, since various mechanisms can be involved in the initiation of VF, such that antiarrhythmic drugs are unlikely to absolutely eliminate arrhythmias and totally prevent VF initiation. Furthermore, recent surveys (such as the Cardiac Arrhythmia Suppression Trial, CAST, II and I [4,5]) have clearly shown limitations to this approach. Thus, a new cardiac protective therapy is needed. For this reason, a new approach has been proposed, to use a new class of antiarrhythmic drugs [6], which can enhance spontaneous termination of VF, once it occurs. In several animal species, and even, though rarely, in humans, VF can revert spontaneously into sinus rhythm, resulting in the non-fatal TVF. It has been previously found that several factors contribute to the ability to self-defibrillate. For example, self-defibrillation is a normal feature of young mammals, but this ability decreases with age [7]. Such spontaneous defibrillation requires a relatively high degree of intercellular synchronization [8], and is enhanced by increased sympathetic activity. Thus, treatments with compounds that elevate extraneuronal catecholamine levels in the heart enhance self-defibrillation and administration of β -adrenergic blockers abolishes this activity [9].

In order to design and synthesize new, more potent and selective defibrillatory drugs, it has been found that certain dibenzoazepins (imipramine, desipramine, maprotiline and bonnecore) and phenothiazins (chlopromazin, moricizine and trifluoperazin), induce self-defibrillation and increase the threshold for electrical fibrillation [10, 11]. Moreover, tricyclic antidepressants, in addition to their antiarrhythmic and defibrillating effects, have the ability to decrease the ischemic area in the heart following coronary occlusion [12]. However, these cardio-protective effects of the compounds were expressed when relatively high doses were used, resulting in a low therapeutic index.


There is thus a need for, and it would be useful to have, pharmaceutically effective compounds which are safe and useful for the

treatment of ventricular fibrillation, particularly for the induction of TVF once SVF has been initiated, and for both treating and preventing pathological conditions associated with VF.

5 SUMMARY OF THE INVENTION

The present invention relates to 5(N-acyl)-derivatives and 5(N-β-aminoalcohol)-derivatives of 11-Oxo-10,11-dihydro-dibenzo [b,e][1,4] diazepin and 10,11-dihydro-dibenzo[b,f]azepin, compositions including same, methods of their synthesis, purification and formulation and their use in
10 prevention and treatment of cardiac disorders. It is shown herein for the first time that these new tricyclic compounds and some previously known tricyclic compounds have been synthesized and have been shown to have substantial activity as chemical defibrillating agents.

According to the present invention, there is provided a compound
15 having a general formula (I):



wherein A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched
20 alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nC*HOHCH₂NR'R'' (the chiral C, which is marked by * can be the R enantiomer, the S enantiomer, be in a racemic mixture or in any other ratio between the R and S enantiomers), wherein n is
25 an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts

thereof.

Preferably, R_1 is selected from the group consisting of β -amino-alcohol, $C(=O)(CH_2)_nNR'R''$ and $(CH_2)_nCHOHCH_2NR'R''$ wherein n is an integer and further wherein the chiral carbon atom can be the R or S anantiomer, a racemic mixture thereof or a mixture of any ratio thereof; and R' , R'' are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl; and pharmaceutically acceptable salts thereof. Examples of suitable alkyl moieties include but are not limited to *iso*-propyl, *iso*-butyl, *tert*-butyl and *sec*-butyl. Most preferably, R'' is *iso*-propyl.

According to a preferred embodiment of the present invention, A and B are each an alkyl chain, more preferably a CH moiety, R_2 , R_3 , R_4 and R_5 are each hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$ and $(CH_2)_nCHOHCH_2NR'R''$, n being 0-5. Preferably, R and R' are each hydrogen and R'' is selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl and *tert*-butyl.

According to a preferred embodiment of the present invention A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R, R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$ and $(CH_2)_nCHOHCH_2NR'R''$, n being 0-5.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention relates to a group of compounds, based upon the general backbone structure of tricyclic antidepressants, namely, 11-oxo-dibenzodiazepins and dibenzoazepins N-substituted at the 5 position, as well as to pharmaceutical compositions of these compounds and to their use in the treatment and prevention of ventricular fibrillation and ischemic damage by local or systemic application. More specifically, these compounds are demonstrated to have a defibrillating effect on ventricular fibrillation, once it actually occurs.


Previous studies, aimed at characterizing the structure-activity relationships of dibenzoazepins and phenothiazines accountable to improved defibrillating activity, have indicated the relevance of several structural features of the backbone of these molecules for their efficacy against ventricular fibrillation. First, activity of the tricyclic compounds correlated with higher (more bent) dihedral angle between the two benzo rings in the tricyclic skeleton. This angle is also considered to play a detrimental role in the type of central nervous system activity of these compounds, as well as their different selectivity towards catecholamine reuptake systems (such as noradrenaline, serotonin and dopamine). Second, compounds with 5-N-substituted secondary aminoalkyl side chains (such as desipramine) exhibit higher defibrillatory activity, as opposed to tertiary alkylamine (such as imipramine) and lastly, transition from aminoalkyl to aminoacyl in the side chain at position 10 of the phenothiazine tricyclic nucleus results in an increase in antiarrhythmic activity and decrease in psychotropic activity [10].

The development of the disclosed class of tricyclic compounds was based on the rationalized design of new compounds, aimed at more focused and selective activity as chemical defibrillators, as well as identifying additional molecules which are able to overcome shortcomings of the presently utilized approaches (electrical defibrillation, antiarrhythmic drugs, described above), and which are able to convert the fatal sustained ventricular fibrillation to the non-fatal transient one.

The experiments described below in the Examples section demonstrate that the disclosed compounds are indeed effective in transforming the potentially fatal VF type, SVF, to the spontaneously-defibrillating type, TVF. In addition, the preferred structure is indicated in terms of a structure-activity-relationship, indicating the importance of certain structural elements in obtaining potent, selective therapeutic activity, and minimizing untoward side effects. Thus, a compound according to the present invention includes derivatives of 5-(N-alkyl), 5-(N-acyl) and 5-(N- β -aminoalcohol) dibenzoazepins of the

6

general formula (II):



[II]

wherein R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, $C(=O)(CH_2)_nNR'R''$ or $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

Preferably, R_1 is selected from the group consisting of β -amino-alcohol, $C(=O)(CH_2)_nNR'R''$, and $(CH_2)_nCHOHCH_2NR'R''$ wherein n is an integer and R' , R'' are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl; and pharmaceutically acceptable salts thereof. Examples of suitable alkyl moieties include but are not limited to *iso*-propyl, *iso*-butyl, *tert*-butyl and *sec*-butyl. Most preferably, R'' is *iso*-propyl. Also most preferably, R_Q and R_T are each a hydrogen, and q and t are each 4.

The compounds of the present invention are also useful as an active ingredient in a composition for treating or preventing a cardiac disorder, such as ventricular fibrillation, featuring a pharmaceutically effective amount of a tricyclic compound in combination with a pharmaceutically acceptable carrier, in which the tricyclic compound is of a general formula (I):



wherein A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

Preferably, R₁ is selected from the group consisting of β-amino-alcohol, C(=O)(CH₂)_nNR'R'', and (CH₂)_nCHOHCH₂NR'R'' wherein *n* is an integer and R', R'' are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl; and pharmaceutically acceptable salts thereof. Examples of suitable alkyl moieties include but are not limited to *iso*-propyl, *iso*-butyl, *tert*-butyl and *sec*-butyl. Most preferably, R'' is *iso*-propyl.

According to a preferred embodiment of the present invention, A and B are each an alkyl chain, more preferably a CH moiety, R₂, R₃, R₄ and R₅ are each hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'' and (CH₂)_nCHOHCH₂NR'R'', *n* being 0-5. Preferably, R and R' are each hydrogen and R'' is selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl and *tert*-butyl.

According to a preferred embodiment of the present invention A is CR₂R₃ or C=O and B is CR₄R₅; R, R₂, R₃, R₄, R₅ and R₆ are each a hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'' and (CH₂)_nCHOHCH₂NR'R'', *n* being 0-5. More preferably, *n* is 1 or 2.

Hereinafter, the term "tricyclic compound" refers to 5-(N-acyl) or 5-(N-alkylβaminoalcohol)-derivatives or 5-(N-alkyl)-derivatives of

10,11-dihydro-dibenzo[b,f]azepin or 5-(N-acyl) or
5-(N-alkylβaminoalcohol)-derivatives or 5-(N-alkyl)- derivatives of
11-Oxo-10,11-dihydro-dibenzo[b,e][1,4] diazepin compounds of the present
invention.

5 Hereinafter, the term "derivative" refers to the result of a chemically
altering, modifying or changing a molecule or a portion thereof, such that the
molecule either maintains or increases its functionality.

Hereinafter, the term "pharmaceutically acceptable carrier" refers to a
carrier or a diluent that does not cause significant irritation to an organism and
10 does not abrogate the biological activity and properties of the administered
compound.


Hereinafter, the term "pharmaceutically effective amount" refers to that
amount of the compound being administered which will relieve to some extent
one or more of the symptoms of the disorder being treated.

15 The composition of the present invention may be optionally and
preferably designed for topical application such as a slow release or
transdermal patch of the tricyclic compound. The composition for slow
release includes particles including a slow release carrier (typically, a
polymeric carrier), and the tricyclic compound. Slow release biodegradable
20 carriers are well known in the art. These are materials that may form particles
that may capture therein an active compound(s) and slowly degrade/dissolve
under a suitable environment (e.g., aqueous, acidic, basic, etc.) and thereby
degrade/dissolve in body fluids and release the active compound(s) therein.

Specifically, a slow release formulation or a transdermal patch of the
25 tricyclic compound can be used in patients prone to cardiac disorders, such as
arrhythmias, or with a known history of arrhythmic or fibrillatory episodes.

One particularly preferred embodiment of the present invention is
parenteral administration of the tricyclic compound, for example
intravenously. Further according to the present invention there is provided a
30 method for treating or preventing a cardiac disorder, such as ventricular

fibrillation, in a subject, by administering a pharmaceutically effective amount of a tricyclic compound of a general formula (I):



wherein A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄,
 5 R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer;
 10 R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

15 Preferably, R₁ is selected from the group consisting of β-amino-alcohol, C(=O)(CH₂)_nNR'R'', and (CH₂)_nCHOHCH₂NR'R'' wherein *n* is an integer and R', R'' are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl; and pharmaceutically acceptable salts thereof. Examples of
 20 suitable alkyl moieties include but are not limited to *iso*-propyl, *iso*-butyl, *tert*butyl and *sec*-butyl. Most preferably, R'' is *iso*-propyl.

According to a preferred embodiment of the present invention, A and B are each an alkyl chain, more preferably a CH moiety, R₂, R₃, R₄ and R₅ are each hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'' and (CH₂)_nCHOHCH₂NR'R'',
 25 *n* being 0-5. Preferably, *n* is 1 or 2. Preferably, R and R' are each hydrogen and R'' is selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl and *tert*-butyl.

According to a preferred embodiment of the present invention A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R , R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$ and $(CH_2)_nCHOHCH_2NR'R''$, n being 0-5.

Preferably, this method of treatment with the compositions of the present invention is used as an adjunct or additive therapy for patients with implanted defibrillators, in order to combine the electrical defibrillation with the chemical defibrillation. The utility of such a combination has been previously shown [M.T. Neuman, *PhD Thesis*, 1995, Tel Aviv University, Tel Aviv, Israel].

Herein, the term "treating" includes substantially inhibiting or completely stopping episodes of cardiac dysfunction, such as ventricular fibrillation, in a subject.

Herein, the term "preventing" refers to a method for barring a subject from exhibiting symptoms of a cardiac disorder, such as ventricular fibrillation, or alternatively for at least reducing the likelihood and/or severity of such symptoms arising in the subject. Further according to the present invention there is provided a method of locally treating a disorder of a tissue of a subject comprising the step of locally applying the herein above described composition to the tissue. The method includes the steps of applying the composition to an implant and inserting the implant into a tissue, such as cardiac tissue. Alternatively, the composition can be applied to a transdermal patch, which is applied to the skin for system absorption.

Also according to the present invention, there is provided a method for preventing ischemia in the cardiac tissue of a subject, by administering the above-referenced compound of the present invention to the subject.

A precise understanding of the mechanism by which the tricyclic compounds of the present invention cause such chemical defibrillation is not required in order to practice the present invention. However, while not wishing to be bound to any particular mechanism or theory, it is believed that increased catecholamine levels, induced by the compounds of the present invention, are

involved in the process. Several lines of evidence support this hypothesis. For example, the evaluation of intra- and inter-species differences for the ability to defibrillate spontaneously have indicated the central role of cardiac autoregulation. In particular, TVF appears in animals with predominantly sympathetic autoregulation, while SVF appears in animals with predominantly vagal autoregulation. Within members of the same species, the ability to defibrillate spontaneously is a normal feature of young mammals, and this ability decreases with age. Respectively, cardiac autoregulation in young mammals is dominantly sympathetic and turns to a vagal predominance with age.

Furthermore, administration of either β -adrenergic blockers (e.g., propranolol or pindolol) or a parasympathomimetic agonist (e.g., acetylcholine or metacholine) in mammals exhibiting TVF, prolongs the duration of TVF and even transforms it into SVF. Lastly, self-defibrillation requires a relatively high degree of intercellular synchronization, which may be enhanced by elevated catecholamine levels. Thus, compounds which are known to elevate extraneuronal catecholamine levels in the heart, such as dibenzoazepins and phenothiazines, were identified to enhance ventricular self-defibrillation, an effect abolished by co-administration of β -adrenergic blockers [9, 14].

Furthermore, in a recent publication, the efficacy in defibrillating activity of dibenzoazepins and phenothiazines was directly related to their ability to inhibit noradrenaline uptake [10]. Alternatively, the compound, 11-Oxo-10,11-dihydro-5-(N-methyl)-propylaminodibenzo[b,e] [1,4] diazepam, was previously suggested for application as a muscarinic receptor antagonist in PCT Application No. WO 91/10654], supporting the role of sympathetic predominance in potential defibrillating activity.

Thus, further according to the present invention there is provided a method of treating or preventing a cardiac disorder in a subject, by inducing cardiac sympathetic activity by administering the tricyclic compounds of the present invention as hereinabove described.

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions illustrate the invention in a non-limiting fashion. The following protocols and experimental details are referenced in the Examples that follow.


Example 1

Synthesis of 10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl]

5-H-dibenzo[b,f]azepin monohydrochloride compounds

Synthesis of 10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5H-dibenzo[b,f]azepin: The synthesis was performed as known in the literature (Schindler W.; Hafliger F.; *Helvetica Chimica Acta* 1954, **59**, 472-483). To a solution of 5H-10,11-dihydro-dibenzo[b,f] azepin (0.85 gr., 4.359 mmol) in benzene (50 ml), 0.5 ml 3-chloropropionyl chloride (5.225 mmol) was added dropwise. The mixture was refluxed for 3 h, the solvent was removed under reduced pressure and the residue was washed with 5 % aq. HCl, followed by extraction with CH₂Cl₂ (20 ml). The resulting organic layer was dried over Na₂SO₄, and the crude product was purified by flash chromatography (silica gel, hexane-ethyl acetate 8:2), resulting in 1.133 gr. (91 % yield) of 10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5-H-dibenzo[b,f]azepin, in the form of white crystals. NMR (CDCl₃): 7.16 (bs, 8H), 3.82 (m, 2H), 3.46 (m, 1H), 2.85 (m, 2H), 2.51 (m, 1H). MS (CI): 286 (M⁺).

Scheme 1 below illustrates the synthesis and structure of 10,11 dihydro-5-[(3-chloro)1-oxopropyl] 5-H-dibenzo[b,f]azepin:




SCHEME 1 (10)

Synthesis of 10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl]5-H-dibenzo[b,f]azepin monohydrochloride: Synthesis of 10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl]5-H-dibenzo[b,f]azepin derivatives was achieved by reaction of the 10,11-dihydro-5-[(3-chloro)1-oxopropyl]5-H-dibenzo[b,f]azepin as a starting material with the corresponding alkyl amine. The succeeding derivatives, wherein the 3-N- substituted alkyl is a methyl, an ethyl or an iso-propyl, (compounds 15a-c) were prepared following the below-described general procedure: A well-stirred suspension of 10,11-dihydro-5-[(3-chloro)-1-oxopropyl]-5-H-dibenzo [b,f]azepin (1.71 gr., 6.0 mmol) in ethanol (50 ml) was warmed to 65 °C. Alkylamine (10 mmol) was added dropwise. The mixture was stirred for 1 h at 65 °C, and then allowed to cool to room temperature. The mixture was washed with 5 % aq. potassium bicarbonate and extracted with CH₂Cl₂ (20 ml). The organic layer was dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude product was recrystallized from EtOAc at 0 °C. The precipitate was filtered to result in the appropriate free base. The solid was then dissolved in toluene and HCl was bubbled till a precipitate formed. The precipitate was filtered and dried under reduced pressure resulting in the appropriate monohydrochloride salt. Alternatively, wherein bulkier alkyl groups were used for substituting the 3-N alkyl, such as *tert*-butyl, sec-butyl, iso-butyl and benzyl (compounds 15d-g), the following procedure was used: A solution of 10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5-H-dibenzo[b,f] azepin (0.285 gr., 1.0 mmol) in *iso*-propanol (15 ml) and monoamine (15 ml) was refluxed overnight. The solvent was removed under reduced pressure, and the

crude product was recrystallized from EtOAc at 0 °C. The solid was dissolved in toluene and HCl was bubbled till a precipitate was formed. The precipitate was filtered and dried under reduced pressure resulting in the appropriate monohydrochloride salt.

- 5 Scheme 2 below illustrates the synthesis and general structure of 10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl]-5-H-dibenzo[b,f]azepin monohydrochloride of both synthetic routes:




SCHEME 2 (15)

10

- (i) 10,11-dihydro-5-[(3-N-methyl)-1-oxopropyl]-5-H-dibenzo[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 1.126 gr. (67 % yield) of light yellow solid was obtained. ¹H NMR (D₂O): δ 6.87 (brm, 8H), 3.15 (s, 1H), 2.82 (brm, 4H), 2.47 (s, 3H), 2.24 (brm, 3H). FAB/MS 281 (M⁺).
- 15

Scheme 3 below illustrates the structure of 10,11-dihydro-5-[(3-N-methyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:



SCHEME 3 (15 a)

20


- (ii) 10,11-dihydro-5-[(3-N-ethyl)1-oxopropyl]5-H-dibenzo[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 1.129 gr. (64 % yield) of light yellow solid was obtained. ¹H NMR (D₂O): δ 6.89 (brm, 8H), 3.12 (s, 1H), 2.84 (brm, 7H), 2.27
- 25

15

(brm, 2H), 1.02 (t, J=7.4, 3H). FAB/MS 295 (M^+).

Scheme 4 below illustrates the structure of 10,11-dihydro-5-[(3-N-ethyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:

5



SCHEME 4 (15 b)

10

(iii) 10,11-dihydro-5-[(3-N-iso-propyl)1-oxopropyl]5-H-dibenzo


[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 1.219 gr. (66 % yield) of light yellow solid was obtained, with mp 199.1 °C. ^1H NMR (D_2O): δ 6.97 (brm, 8H), 3.14 (m, 1H), 2.97 (m, 4H), 2.67 (m, 1H), 2.42 (m, 1H), 2.38 (m, 2H), 1.08 (d, J=6.6, 6H).

15

FAB/MS 309 (M^+).

Scheme 5 below illustrates the structure of 10,11-dihydro-5-[(3-N-iso-propyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:

20



SCHEME 5 (15 c)

(iv) 10,11-dihydro-5-[(3-N-tert-butyl)1-oxopropyl]5-H-dibenzo


25

[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 280 mgr. (87 % yield) was obtained. ^1H NMR (CDCl_3): δ 7.24 (m, 8H), 3.39 (m, 2H), 2.85 (m, 5H), 2.51 (m, 1H), 1.26 (m, 9H). FAB/MS 323 (M^+).

Scheme 6 below illustrates the structure of 10,11-dihydro-5- [(3-N-tert-butyl)1-oxopropyl]5-H-dibenzo[b,f]azepin monohydrochloride:

30

16



5


SCHEME 6 (15 d)

(v) 10,11-dihydro-5-[(3-N-*sect*-butyl)1-oxopropyl]5-H-dibenzo

[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 241 mg. (75 % yield) was obtained. ¹H NMR (CDCl₃): δ 7.25 (m, 8H), 3.37 (m, 2H), 2.97 (m, 5H), 2.79 (m, 2H), 1.52 (m, 2H), 0.99 (m, 6H). FAB/MS 323 (M⁺).

10

Scheme 7 below illustrates the structure of 10,11-dihydro-5-[(3-N-*sect*-butyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:



15

SCHEME 7 (15 e)

(vi) 10,11-dihydro-5-[(3-N-*iso*-butyl)1-oxopropyl]5-H-dibenzo


20

[b,f]azepin monohydrochloride: The synthesis was performed according to the above synthetic scheme. 264 mg. (82 % yield) was obtained. ¹H NMR (CDCl₃): δ 7.23 (m, 8H), 3.35 (m, 2H), 2.82 (m, 4H), 2.47 (m, 2H), 1.84 (m, 1H), 0.95 (d, J=6.6 Hz, 3H), 0.89 (d, J=6.6 Hz, 3H). FAB/MS 323 (M⁺).

25

Scheme 8 below illustrates the structure of 10,11-dihydro-5- [(3-N-*iso*-butyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:


17

**SCHEME 8 (15 f)**


(vii) 10,11-dihydro-5-[(3-N-benzyl)1-oxopropyl]5-H-dibenzo

[b,f]azepin monohydrochloride: The synthesis was performed according to
 10 the above synthetic scheme. 367 mg. (67 % yield) was obtained. ¹H NMR
 (CDCl₃): δ 7.23 (m, 8H), 3.35 (m, 2H), 2.82 (m, 4H), 2.47 (m, 2H), 1.84 (m,
 1H), 0.95 (d, J=6.6 Hz., 3H), 0.89 (d, J=6.6 Hz, 3H). FAB/MS 357 (M⁺).

Scheme 9 below illustrates the structure of 10,11-dihydro-5- [(3-N-
 benzyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin monohydrochloride:


**SCHEME 9 (15 g)**

Scheme 9a describes the synthesis of the β-amino alcohol derivative
 according to the present invention, which was performed in two stages.

**SCHEME 9a**

10,11-dihydro-5-[N-2 methyloxirane]5-H-dibenzo[b,f]azepin (20).**20r, 20s (Stage I):**

To a solution of 5H-10,11-dihydro-dibenzo[b,f] azepin (1.320 g, 6.711 mmol, see Scheme 1, above) in benzene (50 ml) was added NaNH₂ (0.5 gr). The mixture was refluxed for 2 hr and epichlorohydrin (1 ml, 12.810 mmol) was added dropwise. The mixture was refluxed for 6 hr. The solvent was removed under reduced pressure, and the residue was washed with 5% aq HCl, and extracted with CH₂Cl₂ (20 ml). The organic layer was dried over Na₂SO₄ and the crude product was purified by flash chromatography (silica gel, hexane-ethyl acetate 9.5:0.5) to give **20**, (0.75 g, 45%) in the form of white powder. ¹H NMR (chloroform): 7.07 (bs, 4H), 6.93 (m, 2H), 6.73 (bt, 2H) 3.91 (m, 2H), 3.16 (m, 4H), 3.05 (m, 1H), 2.67 (d, 1H), 2.55 (d, 1H). MS (CI): 251 (M⁺). (Scheme 9b)

**SCHEME 9b**

10,11-dihydro-5-[N-β iso-propylamino-2propanol)]5-H-dibenzo[b,f]azepin monohydrochloride, 25 bi, 25 bis, 25 bir (Stage II)

General procedure: A suspension of **20** (1.5 g, 5.0 mmol) in *iso*-propanol (50 ml) was warmed to 30 °C, *iso*-propyl amine (10 mmol) was added dropwise, the mixture was stirred overnight at this temperature and then allowed to cool to room temperature. The solvent was removed under reduced pressure, and the crude product was recrystallized from ethyl acetate at 0 °C. The precipitation was filtered to give the appropriate free base. The solid was dissolved in toluene and HCl was bubbled until a precipitate reappeared. The precipitation was filtered and dried under reduced pressure to give 25 bi salt.

¹H NMR (chloroform): 7.07 (bs, 4H), 6.93 (m, 2H), 6.73 (bt, 2H) 3.79 (m, 1H), 3.15 (s, 4H), 2.78 (m, 1H), 2.72 (d, 2H), 2.55 (d, 2H), 1.01 (d, 6H). MS (CI): 311 (M⁺).

Example 2


5

Synthesis of 11-Oxo-10,11-dihydro-5-

[(N-alkyl)loxopropyl]-5-H-dibenzo[b,e][1,4]diazepin monohydrochloride
compounds

Synthesis of 11 - Oxo - 10, 11 - dihydro - 5H - dibenzo [b,e] [1,4] diazepin: The synthesis was performed according to the below synthetic
10 scheme. A suspension of 2-chlorobenzoic acid (5.08 gr., 31.81 mmol), o-phenylenediamine (3.46 gr., 31.48 mmol), copper powder (2.14 gr., 31.7 mmol) and molecular sieves (3A) in chlorobenzene (100 ml) was vigorously stirred at 130 °C for 8 h. The hot mixture was rapidly filtered and the filtrate was concentrated under reduced pressure. The solid precipitate was collected
15 by filtration and then recrystallized from EtOH resulting in 11-Oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin 5.48 gr. (82 % yield) in the form of bright yellow powder. ¹H NMR (acetone): 8.89 (s, 1H), 7.80 (d, J=7.7 Hz., 1H), 7.33 (t, J=7.3 Hz., 1H), 7.07 (m, 6H). FAB/MS: 211 (M⁺).

Scheme 10 below illustrates the synthesis and structure of
20 11-Oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin monohydrochloride:



SCHEME 10 (1)


Synthesis of 11-Oxo-10,11-dihydro-5-[(3-chloro)1-oxopropyl]

5-H-dibenzo[b,e][1,4]diazepin: The synthesis was performed according to the below synthetic scheme. To a solution of 11-Oxo-
30 10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin (0.376 gr., 1.79 mmol) in dry

20

THF, (10 ml) NaNH₂ (0.132 gr., 3.39 mmol) was added. The mixture was cooled to 0 °C, and 0.2 ml 3-chloropropionyl chloride (2.09 mmol) was added dropwise. The mixture was stirred for 30 min at 0 °C, allowed warming to room temperature, washed with 5 % aq. potassium bicarbonate and extracted with CH₂Cl₂ (20 ml). The resulting organic layer was dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude product was crystallized from ether, resulting in 0.467 gr. (87 % yield) of 11-Oxo-10,11-dihydro-5-[(3-chloro)1-oxopropyl] 5-H-dibenzo[b,e] [1,4]diazepin in the form of a yellow solid, mp 241-242 °C. ¹H NMR (CDCl₃): 8.78 (s, 1H), 7.98 (s, 1H), 7.59 (s, 1H), 7.4-7.26 (m, 6H), 3.77 (m, 4H). FAB/MS: 301 (M⁺).

Scheme 11 below illustrates the synthesis and structure of 11-Oxo 10,11-dihydro-5-[(3-chloro)1-oxopropyl] 5-H-dibenzo[b,e] [1,4] diazepin :




SCHEME 11 (6)

Synthesis of 11-Oxo-10,11-dihydro-5-[(N-alkyl)1-oxopropyl]5-H-dibenzo[b,e] [1,4]diazepin monohydrochloride: The synthesis of the below described 11-Oxo-10,11-dihydro-5-[(N-alkyl)1-oxopropyl]5-H- dibenzo [b,e][1,4]diazepin hydrochloride compounds, 11a-c, was performed by reacting 11-Oxo-10,11-dihydro-5-[(3-chloro)1-oxopropyl] -5-H-dibenzo[b,e][1,4]diazepin, as a starting material, with the appropriate alkyl amine. A well-stirred suspension of 11-Oxo-10,11-dihydro-5-[(3-chloro)1-oxopropyl]-5-H-dibenzo[b,e][1,4]diazepin (1.5 gr., 5.0 mmol) in ethanol (50 ml) was warmed to 65 °C. Alkylamine (10 mmol) was added dropwise. The mixture was stirred for 1 h at 65 °C, and then allowed to cool to room temperature. The mixture was then washed with 5 % aq. potassium

bicarbonate and extracted thrice with CH_2Cl_2 (20 ml). The organic layer was dried over Na_2SO_4 , filtered and the solvent was removed under reduced pressure. The crude product was recrystallized from EtOAc at 0 °C. The precipitate was filtered to result in the appropriate free base. The solid was then dissolved in toluene and HCl was bubbled till a precipitate formed. The precipitate was filtered and dried under reduced pressure resulting in the appropriate hydrochloride salt.

Scheme 12 below illustrates the synthesis and general structure of 11-Oxo-10,11-dihydro-5-[(N-alkyl)1-oxopropyl] 5-H-dibenzo[b,e] [1,4]diazepin monohydrochloride:




SCHEME 12 (11)

(i) *Synthesis of 11-Oxo-10,11-dihydro-5-[(N-methyl)1-oxopropyl] 5-H-dibenzo[b,e] [1,4]diazepin monohydrochloride:*


The synthesis was performed according to the above synthetic scheme. The compound, in the form of a light-pink solid was obtained, 627 mg. (44 % yield), with mp=223-225 °C. ^1H NMR (D_2O): δ 7.33 (br m, 8H), 3.06 (t, $J=6$ Hz, 2H), 2.9 (m, 1H), 2.48 (s, 3H), 2.36 (br m, 1H). FAB/MS 297 (M^+).

Scheme 13 below illustrates the structure of 11-Oxo-10,11-dihydro-5-[(3-N-methyl)1-oxopropyl] 5-H-dibenzo[b,e][1,4]diazepin monohydrochloride:



SCHEME 13 (11 a)

(ii) *Synthesis of 11-Oxo-10,11-dihydro-5-[(N-ethyl)1-oxopropyl]-5-H-dibenzo[b,e][1,4]diazepin monohydrochloride:* The synthesis was performed according to the above synthetic scheme. The compound, in the form of light-yellow solid, was obtained, 1.023 gr. (66 % yield), with mp 243-245 °C. ¹H NMR (D₂O): 7.40 (br m, 8H), 3.08 (t, J=6.1 Hz., 2H), 2.86 (m, 3H), 2.38 (m, 1H), 1.06 (t, J=7.3, 3H). FAB/MS: 311 (m⁺). Scheme 14 below illustrates the structure of 11-Oxo-10,11-dihydro - 5 - [(N-ethyl)1-oxopropyl] - 5 - H-dibenzo [b,e] [1,4] diazepin hydrochloride:




SCHEME 14 (11 b)

(iii) *Synthesis of 11-Oxo-10,11-dihydro-5-[(N-iso-propyl)-1-oxopropyl]-5-H-dibenzo[b,e] [1,4]diazepin monohydrochloride:* The synthesis was performed according to the above synthetic scheme. The compound, in the form of light-orange solid, was obtained, 791 mgr. (49 % yield). ¹H NMR (D₂O): 7.35 (br m, 8H), 3.05 (br m., 3H), 2.85 (m, 1H), 2.33

(m, 1H), 1.08 (t, J=7.3, 3H). FAB/MS: 323 (m^+).

Scheme 14 below illustrates the structure of 11-Oxo-10,11-dihydro-5-[(N-*iso*-propyl) 1-oxopropyl] 5-H-dibenzo [b,e] [1,4] diazepin monohydrochloride:



SCHEME 15(11 c)

Example 3


Synthesis of 10,11-dihydro-5-[N-β isopropylamino- 2propanol] 5-H-dibenzo [b,f]azepin (25bi). 25bir, 25bis monohydrochloride compounds

10,11-dihydro-5-[N-2 methyloxirane]5-H-dibenzo[b,f]azepin (20).

20r, 20s: To a solution of **5** (1.320 g, 6.711 mmol) in benzene (50 mL) was added NaNH_2 (0.5 gr). The mixture was refluxed for 2 hr and the appropriate epichlorohydrin (1 mL, 12.810 mmol) was added dropwise (racemic to obtain **20**, R enantiomer to obtain **20r** and S enantiomer to obtain **20s**. The mixture was refluxed for 6 hrs. The solvent was removed under reduced pressure, and the residue was washed with 5% aq HCl, and extracted with CH_2Cl_2 (2 x 20 mL). The organic layer was dried over Na_2SO_4 and the crude product was purified by flash chromatography (silica gel, hexane-ethyl acetate 9.5:0.5) to give **20**, (0.75 g, 45%) in the form of white powder. ^1H NMR (chloroform): 7.07 (bs, 4H), 6.93 (m, 2H), 6.73 (bt, 2H) 3.91 (m, 2H), 3.16 (m, 4H), 3.05 (m, 1H), 2.67 (d, 1H), 2.55 (d, 1H). MS (CI): 251 (M^+).

Scheme 16 below illustrates the synthesis and structure of 10,11-dihydro- 5-[N-2 methyloxirane]5-H-dibenzo[b,f]azepin (20). 20r, 20s

24



SCHEME 16(20, 20r, 20s)


5 10,11-dihydro-5-[N- β isopropylamino-2propanol)] 5-H-dibenzo
[b,f]azepin monohydrochloride, 25 bi, 25 bis, 25 bir:

General procedure: A suspension of **20** (1.5 g, 5.0 mmol) in *iso*-propanol (50 ml) was warmed to 30 °C, *iso*-propylamine (10 mmol) was added dropwise, the mixture was stirred overnight at this temperature and then allowed to cool to room temperature. The solvent was removed under reduced
10 pressure, and the crude product was recrystallized from ethyl acetate at 0 °C.

The precipitation was filtered to give the appropriate free base. The solid was dissolved in toluene and HCl was bubbled until a precipitation reappeared. The precipitation was filtered and dried under reduced pressure to give 25 bi salt. ¹H NMR (chloroform): 7.07 (bs, 4H), 6.93 (m, 2H), 6.73 (bt,
15 2H) 3.79 (m, 1H), 3.15 (s, 4H), 2.78 (m, 1H), 2.72 (d, 2H), 2.55 (d, 2H), 1.01 (d, 6H). MS (CI): 311 (M⁺).

Scheme 17 below illustrates the synthesis and structure of 10,11-dihydro-5-[N- β isopropylamino-2propanol)]5-H-dibenzo[b,f]azepin monohydrochloride, 25 bi, 25 bis and 25 bir.

25



SCHEME 17(25bi, 25bir, 25bis)

Example 4

Antiarrhythmic defibrillating activity of
tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin compounds

10,11-dihydro-5-[(3-N-alkyl)1-oxopropyl] 5-H-dibenzo[b,f]azepin
monohydrochloride, 10,11-dihydro-5-[N-isopropylamino-2propanol]
5-Hdibenzo [b,f]azepin monohydrochloride and 11-Oxo-10,11- dihydro – 5 -
10 [(N-alkyl)1 - oxopropyl] – 5 - H-dibenzo [b,e] [1,4] diazepin hydrochloride
were synthesized as is described hereinabove and tested for their effectiveness
in transforming SVF to TVF, as described herein. The desired outcome was
determined to be the ability of the drug molecule to reduce or abolish the
occurrence of artificially induced SVF, and its transformation to the
15 spontaneously defibrillating TVF. The experimental method was as follows.

Hydrochloride salts of the compounds were dissolved in saline.
Activity of each compound was tested in cats of both sexes. Cats were
anesthetized with 15-25 mg/kg intravenous sodium pentobarbital. The tested
compounds were injected intravenously (1-3 mg/kg). The heart of each
20 experimental subject was exposed through midline thoracotomy, and a room
air respirator was applied through a tracheal cannula. Lead II
electrocardiogram and intra-arterial blood pressure was recorded on a Grass

Polygraph (Grass Instrument Co., Quincy, MA, USA).

Fibrillating stimuli (a train of rectangular pulses of 2 to 15 V, 100 pulses/sec and duration of 0.1 to 1.0 msec, for a period of 1 sec) were delivered through two silver needle electrodes attached to the pericardium on the left ventricle. Fibrillating stimuli were one and a half to twice the strength of the fibrillating threshold.

Animals were designated as having SVF of VF failed to terminate spontaneously within 90 sec, and required electrical defibrillation. Animals that exhibited two to five consecutive episodes of VF of short (20 to 60 sec) duration were designated as having TVF. VF was induced before and after drug administration, according to a previously described procedure [13]. The type of VF was examined before and 2 to 3 min after drug treatment. Each cat served as its own control. In some experiments, a β -adrenergic blocker (propranolol, 0.1-0.6 mg/kg) was administered after drug administration, in order to evaluate the neutralizing effect of the blocker on the compound-induced catecholamine levels. Table 1 below presents the results.

TABLE 1

Compound	Relative activity in dosage of 1 mg/kg	Relative activity in dosage of 2 mg/kg	Relative activity in dosage of 3 mg/kg
15a	50%	67%	100%
15b	50%	75%	100%
15c	64%	67%	83%
15d	44%	67%	100%
15e	0	0	33%
15f	0	0	0
15g	0	0	0
11a	0	-	50%
11b	0	50%	50%
11c	0	0	0
25bi	100%	100%	-
25bir	50%	100%	-
25bis	100%	100%	-

a. TVF /VF (%)

Example 5

Suitable formulations for administration of
tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin compounds

5 The tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives of
the present invention, including free base or salt form, can be administered to a
subject in a number of ways, which are well known in the art. Hereinafter the
term “tricyclic dibenzoazepin derivatives” refers to the group of dibenzoazepin
derivatives in free base form and the group of dibenzoazepin derivatives in a
10 salt form. Hereinafter the term “tricyclic dibenzodiazepin derivatives” refers to
the group of dibenzodiazepin derivatives in free base form and the group of
dibenzodiazepin derivatives in a salt form. Hereinafter, the term “subject”
refers to the human or any lower animal to which the tricyclic dibenzoazepin
or 11-Oxo-dibenzodiazepin derivative is administered. For example,
15 administration may be done topically (including opthalmically, vaginally,
rectally, intranasally), orally, or parenterally, for example by intravenous bolus
or drip, intraperitoneal, subcutaneous, or intramuscular (cardiac) injection.

Formulations for topical administration may include but are not limited
to lotions, ointments, gels, creams, suppositories, drops, liquids, sprays,
20 transdermal patches and powders. Conventional pharmaceutical carriers,
aqueous, powder or oily bases, thickeners and the like may be necessary or
desirable. In addition to the formulations described previously, a compound of
the present invention may also be formulated as a depot preparation. Such
long acting formulations may be administered by implantation (for example
25 subcutaneously or intramuscularly) or by intramuscular injection. Thus, for
example, the preparation may be formulated with suitable polymeric or
hydrophobic materials (for example, as an emulsion in an acceptable oil) or
ion exchange resins, or as sparingly soluble derivatives such as sparingly
soluble salts.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, sachets, capsules or tablets. Thickeners, diluents, flavorings, dispersing aids, emulsifiers or binders may be desirable.

5 Formulations for parenteral administration may include but are not limited to sterile aqueous solutions, which may also contain buffers, diluents and other suitable additives.

Dosing is dependent on the severity of the symptoms of arrhythmic or fibrillating occurrence and on the responsiveness of the subject to the tricyclic
10 dibenzoazepin derivatives. Persons of ordinary skill in the art can easily determine optimum dosages, dosing methodologies and repetition rates.

Example 6

Method of treatment or prevention of ventricular fibrillation

As noted above, the compounds of the present invention, which are
15 tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives, have been shown to be effective defibrillating agents. The following example is an illustration only of a method of treating VF with the dibenzoazepin and 11-Oxo-dibenzodiazepin derivatives, and is not intended to be limiting.

The method includes the step of administering the tricyclic
20 dibenzoazepin or 11-Oxo-dibenzodiazepin derivatives, in a pharmaceutically acceptable carrier as described in Example 3 above, to a subject to be treated. The tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is administered according to an effective dosing methodology, preferably until a predefined endpoint is reached, such as the prevention of VF occurrence or
25 abnormal cardiac activity. Optionally and preferably, the compound is administered parenterally.

According to another preferred embodiment of the present invention, the compound is used as an adjunct or additive treatment for a patient who has received an implanted defibrillator, such that the compound is administered to
30 the patient as previously described.

Example 7Method of manufacture of a medicamentcontaining a tricyclic dibenzazepin and 11-Oxo-dibenzodiazepin derivative

5 The following is an example of a method of manufacturing a tricyclic dibenzoazepin and 11-Oxo-dibenzodiazepin derivative. First, the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is synthesized in accordance with good pharmaceutical manufacturing practice. Examples of methods of synthesizing the tricyclic dibenzoazepin and
10 11-Oxo-dibenzodiazepin derivatives were given previously herein. Next, the tricyclic dibenzoazepin or 11-Oxo-dibenzodiazepin derivative is placed in a suitable pharmaceutical carrier, as described in Example 3 above, again in accordance with good pharmaceutical manufacturing practice.

15 It will be appreciated that the above descriptions are intended only to serve as examples, and that many other embodiments are possible within the spirit and the scope of the present invention.

20 Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

LIST OF REFERENCES CITED


1. Olshausen K.V., Witt T., Pop T., Treese N., Bethge K., Meyer J. Sudden cardiac death while wearing a Holter monitor. *Am. J. Cardiol.*, 67: 381-386, 1991.
2. Vaughan Williams E.M. Classification of antiarrhythmic drugs. In: Sandoe E., Flasted-Jansen E. Olesen K.H., eds. *Symposium on Cardiac Arrhythmias*. Sudertalje Seden: AB Astra, pp. 449-472, 1970.
3. Sanna G., Archidiacono R. Chemical ventricular defibrillation of the human heart with bretylium tosylate. *Am. J. Cardiol.* 32: 982-986, 1973.
4. CAST Investigators. Preliminary report: Effect of ecainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. *N. Engl. J. Med.* 321: 406-412, 1989.
5. CAST II Investigators - Effect of the antiarrhythmic agent moricizine on after myocardial infarction. *N. Engl. J. Med.* 327: 227-233, 1992.
6. Manoach M., Varon D., Neuman M., Erez M. Editorial – A new group of defibrillatory drugs in the classification antiarrhythmic agent. *Int. J. Cardiol.* 21: 211-217, 1988.
7. Manoach M., Varon D., Erez M. The role of catecholamines on intracellular coupling, myocardial cell synchronization and self ventricular defibrillation. *Mol. Cell. Biochem.* 147: 181-185, 1995.
8. Manoach M., Erez M., Varon D. Properties required for self ventricular defibrillation: Influence of age and drugs. *Cardiol. Elderly.* 1: 337-344, 1993.
9. Manoach M., Beker B., Erez M., Varon D., Netz H. Spontaneous termination of electrically induced ventricular fibrillation. In: Macfarlane P.W. ed. *Progress in Electrophysiology*. London: Pitman Medical Publications Ltd, pp. 361-365, 1979.
10. Erez M., Varon D. Dibenzazepines and phenothiazines – A winding path to defibrillatory antiarrhythmic agents. *Exp. Clin. Cardiol.* 2: 59-63, 1997.
11. Kaverina N.V., Skoldinov A.P. New cardiovascular drugs among

phenothiazine derivatives and related tricyclic systems. Sov. Med. Rev. Cardiol. 3: 81-100, 1987.

12. Manoach M., Varon D., Netz H. Reduction of infarct size following acute coronary occlusion by augmenting collateral blood supply induced by infusion of tricyclic antidepressants. Heart Vessels 3: 80-83, 1987.
13. Manoach M., Varon D., Neuman M., Erez M. The cardioprotective features of tricyclic antidepressants. Gen. Pharmacol. 20: 269-275, 1988.
14. Manoach M., Varon D., Neuman M., Netz H. Spontaneous termination and initiation of ventricular fibrillation as a function of heart size, age, autonomic regulation and drugs: A comparative study on different species of different age. Heart Vessels 2: 56-68, 1987.

WHAT IS CLAIMED IS:

1. A compound having a general formula (II):



wherein R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.


2. The compound of claim 1, wherein R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R' , R_Q , R_T , are each a hydrogen and R'' is as defined above.

3. The compound of claim 2, wherein n is 2 and R'' is an alkyl selected from the group consisting of propyl, *n*-butyl, *tert*-butyl and with the proviso that R'' is not a methyl or an ethyl moiety.

4. The compound of claim 2, wherein n is 1 or 2 and R'' is saturated or unsaturated $(CH_2)_m$ -cycloalkyl or $(CH_2)_m$ -(hetero)aryl, m being 0-5.

5. The compound of claim 4, wherein m is 1 and R'' is an aromatic 6-member ring.

6. A composition for treating or preventing a cardiac disorder, comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier selected from the group consisting of a slow release carrier, an implant and a transdermal patch, said compound being a member of a group having the formula:



wherein,

A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

7. The composition of claim 6, wherein A and B are each a carbon, R₂, R₃, R₄ and R₅ are each a hydrogen, and R₁ is C(=O)(CH₂)_nNR'R'', *n* being 0-5, R' and R are each hydrogen and R'' is as defined above.

8. The composition of claim 7, wherein *n* is 1 or 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

9. The composition of claim 7, wherein n is 1 or 2 and R'' is saturated or unsaturated $(CH_2)_m$ -cycloalkyl or $(CH_2)_m$ -(hetero)aryl, m being 0-5.


10. The composition of claim 9, wherein m is 1 and R'' is an aromatic 6-member ring.

11. The composition of claim 6, wherein A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above.

12. The composition of claim 11, wherein n is 2 and R'' is an alkyl selected from the group consisting of ethyl, propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

13. The composition of claim 11, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

14. A method for treating or preventing a cardiac disorder in a subject, the method comprising the step of administering a pharmaceutically effective amount of a compound, said compound being a member of a group having the formula:



wherein,

A is CH , CR_2R_3 or $C=O$; B is CH , CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 ,

R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl; or A and B together are $C=C$; R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q , R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

15. The method of claim 14, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above.

16. The method of claim 14, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

17. The method of claim 15, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

18. The method of claim 14, wherein A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above.

19. The method of claim 18, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl


20. The method of claim 18, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

21. The method of claim 14, wherein the cardiac disorder is ventricular fibrillation or ischemia.

22. The method of claim 15, wherein said compound is administered to the subject parenterally.

23. The method of claim 15, wherein an implanted defibrillator is implanted in the subject, such that said compound is an adjunct treatment to defibrillation by said implanted defibrillator.

24. A method for stopping the occurrence of ventricular fibrillation in a subject, the method comprising the step of administering a pharmaceutically effective amount of a compound, said compound being a member of a group having the formula:



wherein,

A is CH, CR_2R_3 or $C=O$; B is CH, CR_4R_5 or NR_6 , wherein R_2 , R_3 , R_4 , R_5 and R_6 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl; or A and B together are $C=C$; R_1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and $C(=O)(CH_2)_nNR'R''$, $(CH_2)_nCHOHCH_2NR'R''$, wherein n is an integer; R_Q ,

R_T , R' , and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted $(CH_2)_m$ -(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

25. The method of claim 24, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5, R and R' are each hydrogen and R'' is as defined above..

26. The method of claim 25, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

27. The method of claim 25, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

28. The method of claim 24, wherein A is CR_2R_3 or $C=O$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $C(=O)(CH_2)_nNR'R''$, n being 0-5 and R' is a hydrogen and R'' is as defined above.

29. The method of claim 28, wherein n is 2 and R'' is an alkyl selected from the group consisting of ethyl, propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.


30. The method of claim 28, wherein n is 2 and R'' is saturated or unsaturated $(CH_2)_m$ -(hetero)aryl, m being 0-5.

31. The method of claim 24, wherein said compound is administered

to the subject parenterally.

32. The method of claim 24, wherein an implanted defibrillator is implanted in the subject, such that said compound is an adjunct treatment to defibrillation by said implanted defibrillator.

33. A method of locally treating or preventing a disorder of a tissue of a subject comprising the step of locally applying onto said tissue a composition for treating or preventing a cardiac disorder, said composition comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carrier, said compound being a member of a group having the formula:



wherein A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *t* are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

34. The method of claim 33, wherein the step of locally applying the

composition onto said tissue further comprises the steps of:

- (i) applying the composition to an implant; and
- (ii) inserting said implant into said tissue.


35. The method of claim 34, wherein said tissue is cardiac tissue.

36. The method of claim 32, wherein the step of locally applying the composition onto said tissue further comprises the steps of:

- (i) applying the composition to a transdermal patch; and
- (ii) applying said patch into said tissue.

37. The method of claim 36, wherein said tissue is skin.

38. A method for treating or preventing a cardiac disorder in a subject, the method comprising the step of inducing cardiac sympathetic activity by administering a compound to the subject, said compound being a member of a group having the formula:



wherein,

A is CH, CR₂R₃ or C=O; B is CH, CR₄R₅ or NR₆, wherein R₂, R₃, R₄, R₅ and R₆ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl; or A and B together are C=C; R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or

unsubstituted $(\text{CH}_2)_m$ -(hetero)aryl, and sulfonamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof.

39. The method of claim 38, wherein A and B are each a CH moiety, R_2 , R_3 , R_4 and R_5 are each a hydrogen, and R_1 is $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, n being 0-5 and R and R' are each hydrogen and R'' is as defined above.

40. The method of claim 39, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl and *sec*-butyl.

41. The method of claim 39, wherein n is 2 and R'' is saturated or unsaturated $(\text{CH}_2)_m$ -(hetero)aryl, m being 0-5.

42. The method of claim 38, wherein A is CR_2R_3 or $\text{C}=\text{O}$ and B is CR_4R_5 ; R_2 , R_3 , R_4 , R_5 and R_6 are each a hydrogen, and R_1 is $\text{C}(=\text{O})(\text{CH}_2)_n\text{NR}'\text{R}''$, n being 0-5 and R' is a hydrogen and R'' is as defined above.

43. The method of claim 42, wherein n is 2 and R'' is an alkyl selected from the group consisting of methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, and *tert*-butyl.

44. The method of claim 42, wherein n is 2 and R'' is saturated or unsaturated $(\text{CH}_2)_m$ -(hetero)aryl, m being 0-5.

45. The method of claim 38, wherein the cardiac disorder is ventricular fibrillation or ischemia.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL00/00510

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/55; C07D 223/18, 243/10; A61P 9/00, 9/10

US CL : 514/217, 220; 540/495, 557, 588, 589, 590, 591, 592

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/217, 220; 540/495, 557, 588, 589, 590, 591, 592

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 515 796 A1 (ARZNEIMITTELWERK DRESDEN GMBH) 02 December 1992, see entire document.	6, 14, 16, 21, 24, 31, 33-38 and 45
X	US 5,264,432 A (RUGER et al.) 23 November 1993, see examples 1-17.	6, 14, 16, 21, 24, 31, 33-38 and 45
X	US 5,002,943 A (MIHM et al.) 26 March 1991, see examples 1-15.	6, 14, 16, 21, 24, 31, 33-38 and 45
X	US 5,066,426 A (WANG et al.) 19 November 1991, see example 23.	1, 2, 6, 7 and 11

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

01 February 2001 (01.02.2001)

Date of mailing of the international search report

30 MAR 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Brenda L. Coleman

Bella Collins

Telephone No. 703-308-1235

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15656 A3

- (51) International Patent Classification⁷: A61K 31/55, C07D 223/18, 243/10, A61P 9/00, 9/10
- (74) Agent: EHRLICH, Gal; G.E. Ehrlich (1995) Ltd., Bezalel Street 28, 52521 Ramat Gan (IL).
- (21) International Application Number: PCT/IL00/00510
- (22) International Filing Date: 27 August 2000 (27.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
131685 1 September 1999 (01.09.1999) IL
- (71) Applicant (for all designated States except US): TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. [IL/IL]; Senate House, Technion City, 32000 Haifa (IL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): EREZ, Mordechai [IL/IL]; 19 Shmuel Barkai Street, 69697 Tel Aviv (IL). LEVY, Ofra [IL/IL]; 8 Gedera Street, 49724 Petah Tikva (IL). KEINAN, Ehud [IL/IL]; 8 Moran Street, 23840 Timrat (IL).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
30 August 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRICYCLIC COMPOUNDS AND THEIR USES AS ANTIARRHYTHMIC ANTIFIBRILLATORY AND DEFIBRILLATORY AGENTS



(57) Abstract: A compound having a general formula (II) wherein R₁ is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH₂)_nNR'R'', (CH₂)_nCHOHCH₂NR'R'', wherein *n* is an integer; R_Q, R_T, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH₂)_m-(hetero)aryl, and sulfonylamide; *q* and *r* are each an integer independently selected from 1-4; and

pharmaceutically acceptable salts thereof, and the new therapeutic uses thereof and similar compounds as defibrillating, and/or anti-fibrillatory, and/or anti-arrhythmic and/or anti-ischemic drugs.